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SUMMARY
Elevated plasma levels of fibrinogen have been associated with an 
increased risk of peripheral vascular disease and with elevated levels 
of blood pressure. Furthermore there is some evidence that plasma 
levels of fibrinogen may be determined at least in part by variation 
at the fibrinogen gene loci. This study was undertaken to investigate 
the contribution of variation at the fibrinogen loci with plasma 
fibrinogen levels and to seek association between fibrinogen gene 
variation and the determination of levels of blood pressure and the 
occurance of peripheral vascular disease.
Allele frequencies at the alpha, beta and gamma fibrinogen loci were 
determined in 235 cases and controls from the peripheral vascular 
disease study. The values were alpha/TaqI 0.75 (for A the 2.4Kb 
fragment), 0.25 (for a the 1.6Kb fragment); beta/BclI 0.84 (for B 
the 5.3Kb fragment), 0.16 (for b the 4.2Kb fragment) and 
gamma/KpnI/SacI 0.76 (for D the 14Kb fragment), 0.24 (for d the 11Kb 
fragment). Allele frequencies at the beta fibrinogen locus for the 
Haelll polymorphism were determined using the polymerase chain 
reaction (PCR) in a further 170 of these individuals. The values were 
0.81 (for HI the 0.575Kb and 0.383Kb fragments) and 0.19 (for H2 the 
0.958Kb fragment). The overall genotype frequencies were compared with 
those predicted from the Hardy-Weinberg equilibrium and no significant 
difference was noted. Allele frequencies were compared with previously 
published studies and a significant difference was noted for beta/BclI 
between this study on Scottish subjects and that of Humphries et al. 
(1987) on English subjects (p<0.05) but not between this study and
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Berg and Kierulf (1989) on Norwegian subjects (p>0.80).
Strong linkage disequilibrium was found between the alpha/TaqI and
gamma/KpnI/SacI markers and the beta/BclI and beta/Haelll markers 
which was highly significant at any level (p=l,lxlO-Z7 and 2.24x10"® 
respectively). A lesser association was found between the alpha/TaqI 
and beta/BclI loci (p=6.6x10"^); beta/BclI and gamma/KpnI/SacI markers 
(p=2.5x10-3); alpha/TaqI and beta/Haelll (p=1.3xlO-*) markers and the 
gamma/KpnI/SacI and beta/Haelll markers (p=l.4x10"^). This is
consistent with the known physical order of the loci and suggests a
relative excess of recombination in the alpha/gamma-beta interval.
Fibrinogen levels were determined in the peripheral vascular disease 
case/control study by clotting or nephelometric assays and the
relationship of fibrinogen level to genotype analysed. No
statistically significant association was detected for any of the four 
markers TaqI, Bell, KpnI/SacI and Haelll with respect to fibrinogen 
levels.
The 235 individuals in this study had one of 13 different haplotypes 
with respect to the TaqI, Bell and KpnI/SacI markers. No Statistically 
significant association was detected for any of these haplotypes in
respect of fibrinogen levels. The percentage of phenotypic variability 
was calculated and varies from 2.4-4.9% in the different analyses.
155 individuals were genotyped with respect to the Haelll-beta
polymorphism. There was no association between plasma fibrinogen level 
and any genotype (p=0.58). Differences in genotype distribution 
between cases and controls were analysed using . No significant
difference in distribution was observed (p=0.55). The contribution of 
genotype and smoking status to fibrinogen level was analysed. There 
was no relationship between the Haelll RFLP, smoking and fibrinogen 
level (p=0.58).
The contribution of fibrinogen haplotype to the occurrence of
peripheral vascular disease was assessed by multiple logistic
regression using variables which represent the difference in the log
odds of disease for each haplotype relative to haplotype 1. Haplotype
was found to be a significant predictor of disease after accounting
for other risk factors and there is some consistency in the results
for haplotypes 3 (aa Bb DD) and 5 (Aa Bb Dd) suggesting that they are
significant predictors of disease (p<0.05), over and above the level 
of fibrinogen This effect was most marked for allele differences 
at the Bell (beta locus w i t h  a relative excess of the rarer k allele
(p<0.005) in cases versus controls.
Allele frequencies at the beta fibrinogen locus were determined in 168
individuals in the Ladywell hypertension study. The values were
.Bcll/beta 0.85 (for B the 5.3Kb fragment) and 0.15 (for b the 0.15Kb
fragment). The overall genotype frequencies were compared with those
predicted from the Hardy-Weinberg equilibrium and no significant
difference was noted. A comparison of the Bell genotype distribution
was carried out between the four different groups in the Ladywell
study. No statistically significant difference was recorded in the
genotype distribution in the four groups.
This study was unable to demonstrate a relationship between fibrinogen 
genotype at the alpha, beta or gamma loci and plasma fibrinogen level 
in a large Scottish case and control study of peripheral vascular 
disease. Further no association could be detected between
XI
predisposition to high or low blood pressure and variation at the 
fibrinogen locus. In contrast a statistically significant association 
was detected between fibrinogen haplotype and the occurrence of 
peripheral vascular disease. This suggests that the type of fibrinogen 
produced as a result of genetic variation rather than its level might 
be of importance in the causation of peripheral vascular disease. In 
view of the clinical importance of these observations other studies of 
this nature in peripheral vascular disease and other cardiovascular 
diseases are indicated.
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1.0 INTRODUCTION
Atherosclerosis is the principal factor in the development of 
cardiovascular disease which is the most common cause of death in the 
UK. Well accepted risk factors in the development of atherosclerosis 
include cigarette smoking, hypercholesterolaemia and hypertension. 
There is also increasing evidence that haemostatic factors play an 
important role in thrombogenesis and atherogenesis. For example, 
increased plasma levels of fibrinogen have been shown in longitudinal 
studies to be associated with an increased risk of ischaemic heart 
disease and stroke (Meade et al., 1980, 1986, 1987; Wilhelmsen et al., 
1984). Fibrinogen levels show a prognostic significance comparable to 
that of other major risk factors but to what extent levels of 
fibrinogen are environmentally or genetically influenced is not fully 
understood.
1.1 Fibrinogen Biochemistry
Fibrinogen (MW 340,000) is an abundant plasma glycoprotein with 
an overall length of 450-470 angstroms (Harder et al,. 1982) which 
consists of two sets of three different polypeptide chains. The chains 
are designated alpha, beta and gamma with molecular weights of 66000, 
52000, and 46500, respectively (McKee et al., 1966). The alpha chain 
is the largest of the three chains and contains 625 amino acid 
residues; the beta chain contains 450 and the gamma chain 410 (Watt et 
al., 1978). The complete amino acid sequences of the three chains have 
been established (Henschen and Lottspeich, 1977; Lottspeich and 
Henschen, 1977; Doolittle et al., 1979; Henschen et al., 1979; Watt et 
al., 1979) and indicate considerable homology between the three genes.
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The beta and gamma polypeptides, however, share a significantly higher 
degree of homology with each other than with the alpha chain, 
especially in the carboxy-terminal two thirds (fragment D) (Watt et 
al., 1978; Kant et al., 1983a).
This relationship between the three chains indicates that they 
probably arose by duplication and divergence from a common ancestral 
gene (Doolittle, 1973; Watt et al., 1978; Kant et al., 1983a; Chung et 
al., 1983). There are four carbohydrate clusters on the fibrinogen 
molecule, one on each of the two beta chains and one on each of the
two gamma chains (Iwanager et al., 1968; Pizzo et al., 1972;
Topfer-Petersen et al., 1976). No such cluster is found on the alpha 
chain. Each of the three chains bears valine at the carboxyl terminal 
(Oudke and Iwanaga, 1971). In total there are 29 disulphide bonds, 
three of which hold the dimeric halves of the molecule together and 13 
occur twice per molecule (Harder et al., 1982; Bouma et al., 1978; 
Blomback et al., 1972).
All three chains are synthesised in the liver in hepatic 
parenchymal cells from three individual mRNA species (Foreman and 
Barnhart, 1964; Nickerson and Fuller, 1981; Chung et al., 1980;
Crabtree et al., 1981; 1982). They are processed, glycosylated,
assembled, and eventually secreted into the circulating plasma as a 
mature fibrinogen molecule at a concentration of approximately 3g/L in 
normal blood plasma (Shafer and Higgins, 1988). The rate limiting step 
in the production of fibrinogen is the synthesis of the beta chain 
(Roy et al. ,1990). It therefore, follows that any change in the 
transcription of the beta gene will be reflected in a change in the 
rate of fibrinogen production. Figure 1.1 is a schematic
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Figure 1.1. Schematic diagram of the Fibrinogen Molecule, (a) Central domain (MW 32,600); (b) 
Terminal domain (MW 67,200); (1) Thrombin cleavage site for the release of fibrinopeptide A; (2) 
Thrombin cleavage site for the release of fibrinopeptide B; (3) "disulphide girdle"; (4) thin connecting 
alpha helical coiled coils; (5) carbohydrate attached to gamma chain; (6) fragment D; (7) alpha polar 
appendage; (8) carbohydrate attached to the beta chain.
representation of the fibrinogen molecule modified from that of 
Doolittle (1975).
Fibrinogen participates in the final step of the coagulation 
pathway which can be initiated in one of two ways:
(i) The extrinsic system depends on the complexing of tissue factor 
(such as is exposed to blood in a ruptured atheromatous plaque, or 
those produced by the action of cytokines on endothelial cells) with 
factor VII.
(ii) The intrinsic system can be triggered by negatively charged 
lipoproteins such as chylomicrons or very low density lipoproteins 
which provides an appropriate surface for the activation of factor 
XII (Ganong, 1985). A summary of the coagulation pathway is presented 
in Figure 1.2.
During the coagulation process, thrombin removes fibrinopeptide 
A and B, from the alpha and beta chains respectively, by proteolysis, 
converting fibrinogen to fibrin monomers. After thrombin cleavage, the 
amino terminal residues of the alpha and beta chains are converted 
from alanine and glutamine, respectively, to glycine (Dayhoff, 1972). 
The fibrin monomers then polymerise allowing Factor XIII to catalyse 
the introduction of a small number of covalent bonds between certain 
side chains of adjacent molecules in the polymer, thereby stabilizing 
the fibrin clot (Doolittle, 1973, 1975). Factor XIII susceptible
cross-link sites are present on the alpha and gamma chain, but not the 
beta chain (Harder et al., 1982; Chen and Doolittle, 1970).
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Figure 1.2. Summary of the coagulation cascade.
The dissolution of the fibrin clot, formed during the 
coagulation process, is achieved via the fibrinolytic system by 
proteolytic enzymes such as plasmin (Smith. 1986). The pattern of 
fibrinogen and fibrin breakdown was determined in part to elucidate 
the structure of the fibrinogen molecule. However, it was not until 
1969 that Harder et al. demonstrated the structural relationship 
between the early products of plasmin digestion, fragments X and Y,
and the late digestion products, fragments D and E. The degradation 
fragments (D and E) are important in stimulating macrophages to 
produce interleukin 6 and other hepatocyte stimulating factors, which 
feedback on the liver to increase fibrinogen synthesis (Cook and Ubben 
1990). This mechanism is important both for the maintenance of steady 
state fibrinogen levels and for the acute phase reaction during an 
inflammatory response. Figure 1.3 represents the degradation of 
fibrinogen into its characteristic fragments.
1.2 Fibrinogen-Genetics
In man the alpha, beta and gamma genes are closely linked in a 
50kb DNA segment (Kant et al., 1985) and have been mapped by various 
methods to the long arm of chromosome 4 (Olaisen et al., 1982; Henry 
et al., 1984; Humphries et al., 1984; Kant et al., 1983b, 1985 Marino 
et al., 1986). Aschbacher et al. (1985) used a series of restriction 
fragment length polymorphisms (RFLPs) at the fibrinogen locus to study 
linkage disequilibrium and concluded that the likely order is gamma, 
alpha, beta. This agrees with the order suggested by Kant et al.
(1985). The alpha and gamma genes are transcribed in the 5* to 3* 
direction from one strand of DNA whereas the beta gene is transcribed 
in the 5* to 3* direction from the opposite strand of DNA (Kant et
al., 1985). The alpha gene is 10Kb upstream from the gamma gene and
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Fragment  X 
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Figure 1.3. Schematic diagram of the degredation of fibrinogen by plasmin (After Marder et ai., 1982). 
The conversion of fibrinogen to fragment X involves the removal of the alpha polar appendages. 
Fragment X is converted to fragments Y and D by the splitting of either of the three stranded ropes 
connecting the domains. Fragment Y is further degraded to another fragment D and fragment E.
13Kb downstream from the beta gene. All three genes are approximately
10Kb in length. The alpha gene consists of 5 exons and 4 introns; the
beta gene of 8 exons and 7 introns and the gamma gene 8 exons and 7 
introns (Chung et al., 1983, Kant et al., 1985).
The first fibrinogen gene to be mapped to chromosome 4 was the 
gamma gene. Family studies indicated close linkage between a gamma 
chain variant (FGG) and the MNSs blood group loci, which are known to
map to 4q29-q31 (Olaisen et al., 1982). Henry et al. (1984) employed
gene dosage analysis as well as cDNA clones and somatic cell hybrids 
to assign the fibrinogen genes to 4q21-q31. This region was further 
localised to 4q26-qter by Humphries et al. (1984) who showed that in 
somatic cell hybrids carrying a chromosome 4:12 translocation with a 
break point at 4q26, all three fibrinogen genes segregated with the 
4q26-qter segment. This localisation was confirmed by in situ 
hybridization with the alpha fibrinogen probe which localized the 
distance to 4q29-4q31 (Humphries et al., 1984). Marino et al. (1986) 
further localized the fibrinogen gene cluster to band 4q31.
Several DNA polymorphisms of the fibrinogen genes have been 
reported (Humphries et al., 1984, 1987; Murray et al., 1986; Thomas 
et al.,1991)) and are presented in Table 1.1. A diagram of chromosome 
4 indicating the location of the alpha, beta, and gamma genes and 
their corresponding RFLPs is presented in Figure 1.4.
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Table 1.1. The RFLPs of the Fibrinogen Genes (Human Gene Mapping 10,1990; Thomas et al., 1991)
Map
Location
Locus
Symbol
Probe Enzyme Constant
Bands
Size
Kb
4q31 FGA pFAl TaqI 0.7 2.4
4q31 FGB pHIB2 Hincn 16
Avan 4.3
4.1
Bell 6.0 4.5
2.5
FGB pFB5 Bell 6.6 5.3
4.2
FGFB Bgll 23
18
FGB PCR HaeUI 0.34 0.95
0.57
0.38
4q31 FGG pFGI KpnI/SacI 11
14
il I 111
1 4
1 1
pFGl
0.7kb
2.4
1 . 6  *
pAFI
1.7kb
5.3
4 .2  *.
pFB5
1.45kb
qS1
KpnI/SacI Bel 1 Hae IIITaq 1
.*.0.5 .
PCR
I.Skb
Figure 1.4. Organisation of the human fibrinogen gene locus. The above diagram shows the RFLPs 
produced by enzymes TaqI Bell, KpnI/SacI and Haelll. The band size produced in the absence of the 
polymorphic site is that indicated on the upper band. The presence of a polymorphic site (*) w ill result 
in a reduced band size(s), the lower band. The DNA sequences that create the TaqI and the Bell 
polymorphisms map outside the gene coding region. The TaqI polymorphism is approximately 1000 
bp from the 3’ end of the alpha fibrinogen gene (Humphries et al, 1984). The Bell variable site occurs 
in intron 3 of the beta gene and lies closest to the gene promotor region (Humphries et al., 1987). The 
Haelll variable site is 453bp upstream from the start of transaction of the beta gene (Thomas et al., 
1991). The beta gene is on the opposite strand of DNA to that on the alpha and gamma gene and is 
therefore transcribed in the opposite orientation.
1.3 Fibrinogen Abnormalities
Abnormal fibrinogens can occur as an inherited abnormality 
(reviewed by Menache, 1973) or can occur in some pathological 
conditions such as chronic hepatitis when they are considered to be an 
acquired state (Soria et al., 1968). Dominant inheritance of
dysfibrinogenemia and hypofibrinogenemia is indicated in most family 
pedigrees yet the presence of abnormal and normal molecules indicates 
"autosomal codominant" inheritance. The abnormal fibrinogens are named 
according to the cities where they were discovered (Table 1.2). Many
of the fibrinogens have been shown to have an increased clotting time,
some with pathological consequences. In the most severe circumstances 
the affected molecule may never form a clot. Some of the heritable 
disorders are associated with a decreased rate of fibrinopeptide 
cleavage. The majority, however, have the defect in the second step: 
aggregation of fibrin monomer to form a fibrin gel. Some defects can 
also be associated with the covalent crosslinking of fibrin to form 
an insoluble clot. (Menache, 1973; Ratnoff, 1973).
The first specific amino acid substitution was found in
fibrinogen Detroit (Blomback et al., 1968) where serine is substituted 
for arginine. The location of the replacement is two residues away 
from the amino-terminal glycine of the alpha chain (Blomback and 
Blomback, 1970; Kudryk et al., 1976; Mammen, 1976). It has been 
suggested that this substitution is responsible for the virtual 
abolition of fibrin polymerization in the homozygous individual 
(Mammen et al., 1969, 1976; Menache, 1973). Other fibrinogens such as 
Cleveland, Nancy and Troyes have a normal rate of fibrinopeptide 
release but the second step, fibrin monomer aggregation, is abnormal 
(Forman et al. 1968; Streiff et al., 1971; Soria et al., 1972).
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Fibrinogen Paris I is associated with an abnormality in the gamma 
chain. The affected molecules polymerize poorly and are unable to form 
cross links in the presence of factor XIII. The abnormal gamma chain 
is about 2500 daltons heavier than the normal gamma chain 
corresponding to an additional polypeptide chain of about 22 amino 
acid residues (Budzynski et al., 1974).
Comprehensive listings of the fibrinogen variants have been 
assembled by Menache (1973), Rupp and Beck (1984) and have recently 
been catalogued by Ebert (1990). There are now over 50 known variants. 
The majority of the alpha- and gamma-dysfibrinogenemias have been 
shown to result from missense mutations and the 
beta-dysfibrinogenemias from amino acid substitutions. A tabulation is 
presented in Table 1.2.
1.4 Fibrinogen-Association with Cardiovascular Disease
A number of studies have indicated a possible link between high 
fibrinogen levels and the onset of clinically manifest cardiovascular 
disease. (Stone and Thorp, 1985; O'Connor et al., 1984; Manda et al., 
1989; Wilhelmsen et al., 1984; Kannel et al., 1987; Hampton et al., 
1966; Meade et al., 1979). This hypothesis has been supported by the 
Northwick Park Heart Study (NPHS) which showed that high clotting 
factor levels are predictive for Ischaemic heart disease (IHD) (Meade 
et al., 1980, 1986). However, association does not prove causation. 
Atherosclerotic lesions present several characteristics of an 
inflammatory réponse and fibrinogen is an acute phase protein, 
therefore, the raised fibrinogen concentrations that are associated 
with an increased risk of cardiovascular disease may merely be an
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Table 1.2 Abnormal Fibrinogens
Name Molecular Pathology
Due to an Alpha Chain Defect
AArhus-1 ARG-SER at position 19
Amiens-1 ARG-HIS at position 16
Amiens-2 ARG-HIS at position 16
Bergamo-1 ARG-CYS at position 16
Bergamo-3 ARG-HIS at position 16
Bern 2 ARG-HIS at position 16
Bicetne-1 ARG-HIS at position 16
Birmingham-1 ARG-HIS at position 16
Chapel Hill-2 ARG-HIS at position 16
Clermont-Ferrand-1 ARG-HIS at position 16
Detroit-1 ARG-SER at position 19
Giessen-1 ARG-HIS at position 16
Hershey-2 ARG-CYS at position 16
Hamburg-2 ARG-CYS at position 16
Hamburg-3 ARG-CYS at position 16
Kawaguchi-1 ARG-CYS at position 16
Leitchzield ARG-HIS at position 19
Leogan ARG-CYS at position 16
Lille-1 ASP-ASN at position 7
Long Beach-1 ARG-HIS at position 16
Louisville-1 ARG-HIS at position 16
Manachester-1 ARG-HIS at position 16
Metz-1 ARG-CYS at position 16
Munich-1 ARG-ASN at position 19
New Albany ARG-CYS at position 16
Table 1.2 Continued Abnormal Fibrinogens
Name Molecular Pathology
Osaka-1 ARG-CYS at position 16
Paris-6 ARG-HIS at position 16
Petosky-1 ARG-HIS at position 16
Rouen-1 GLY-VAL at position 12
Schwaizach-1 ARG-CYS at position 16
Seattle-2 ARG-HIS at position 16
Shezhield-2 ARG-HIS at position 16
Stony Brook-1 ARG-CYS at position 16
Sydney-1 ARG-HIS at position 16
Sydney-2 ARG-HIS at position 16
Tonno-1 ARG-CYS at position 16
White Marsh-1 ARG-HIS at position 16
Zurich-1 ARG-CYS at position 16
Due to a Beta Chain Defect
Baltimore-2 ARG-LYS at position 448 
Substitition is a neutral polymorphism
Christchurch-2 ARG-CYS at position 14
New York-1 De ietion 9-27 exon 2 of Beta Gene
Pontoise-2 ' ALA-THR at position 337
Seattle-1 ARG-CYS at position 14
Due to a Gamma Chain Defect
Asahi MET-THR at position 310 
Impaired polymerisation of rib monomer
Baltimore-1 GLY-VAL at position 296
Baltimore-3 ASN-ILE at position 308 
defective fibrin monomer polymerisation
Baltimore-4 ARG-CYS at position 275
Table 1.2 Continued Abnormal Fibrinogens
Name Molecular Pathology
Bergamo-2 ARG-HIS at position 275
Zssen-1 ARG-HIS at position 275
Haiza-1 ARG-HIS at position 275
Kyoto-1 ASN-LYS at position 3089
Kyoto-3 ASP-TYR at position 330
Milano-1 ASP-VAL at position 330
Morioka-1 ARG-LYS at position 275
Nagoya-1 GLN-ARG at position 329
Osaka-2 ARG-CYS at position 275
Oslo-3 Elongation of gamma chain at the L. 
terminal
Paris-1 Abnormally long gamma chains at L. 
terminal
Perugia-1 ARG-HIS at position 275
Saga-1 ARG-HIS at position 275
Tochigi-1 ARG-CYS at position 275
Tokyo-2 ARG-LYS at position 275
Vlissinger-1 6 base deletion give rise to absence of 
asparagine 319 and aspartic acid 320.
index of the severity of the manifest disease. To help overcome this 
problem it has been important to ensure that the measurement of 
fibrinogen precedes the clinical event, and to establish if the level 
of fibrinogen is of pathogenic significance, for example, are high 
levels found in groups at high risk of cardiovascular disease, and low 
levels in those at low risk.
1.4.1 High Risk Situations
The main environmental cause of high fibrinogen levels is 
cigarette smoking. A number of studies have established that
fibrinogen levels are higher in smokers than non-smokers with a higher 
fibrinogen level in ex-smokers than those who have never smoked
(Kannel et al., 1984, 1987; Meade et al., 1987; Balleisen et al., 
1985; Lee et al., 1990). The NPHS showed that stopping/starting or 
resuming smoking was associated with a decrease or an increase in 
plasma fibrinogen levels of about 0.15 g/L. These changes would lower 
or raise the risk of IHD by approximately 20% (Meade et al., 1987).
Increasing age is probably the most powerful predictor of the 
risk of cardiovascular disease (CVD). Fibrinogen levels have been 
shown to increase with age in both men and women (Hampton et al., 
1966; Ogston and Ogston, 1966 Lee et al., 1990) although in women 
there is evidence that the rise of fibrinogen with age may be 
correlated to menopausal status, with higher fibrinogen levels 
recorded in post- than pre-menopausal women (Meade et al., 1983).
Oral contraceptive users have been shown to have an increased 
risk of thromboembolic disease and the risk has been shown to rise 
with increasing oestogen dose (Inman et al., 1970) with a subsequent
Page 8
elevation in fibrinogen concentration (Meade et al., 1977, 1979,
1980b, 1984).
Diabetes is associated with accelerated atherosclerosis. Levels 
of fibrinogen have been found to be significantly raised in insulin 
dependent diabetics. In addition, fibrinogen levels are increased in 
diabetics with microvascular disease in comparison to those without
this complication (Wardle et al., 1973; Fuller et al., 1979).
There may be a psychological/social influence on fibrinogen 
levels. Mortality from coronary heart disease in civil servants in the 
lowest grade of employment (unskilled workers) has been found to be 
about three times that of men in the highest grade of employment
(professional classes) with a significant difference in plasma
fibrinogen concentration being recorded in the lower grade employment 
group (Markowe et al., 1985; Lee et al., 1990). Additionally Markowe 
et al. (1985) reported a relationship between fibrinogen levels and 
job satisfaction with the highest levels being recorded in those 
reporting dissatisfaction.
1.4.2 Low Risk Situations
Plasma fibrinogen levels appear very resistant to dietary 
influences (Meade et al., 1986). Vegetarians have a lower incidence of 
IHD compared to non-vegetarians although fibrinogen levels are 
reported to be similar in the two groups (Philips et al., 1978; Haines 
et al., 1980). There is, however, evidence that white fish consumption 
is associated with an increased fibrinogen level (Lee et al., 1990).
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Moderate alcohol consumption has an apparently protective effect 
against ischaemic heart disease (IHD) and has been correlated with a 
lower fibrinogen level in drinkers compared to non-drinkers (Meade et 
al,, 1979, 1984, 1987). This effect is maintained for drinkers in each 
of the three smoking groups, current, ex- and non-smokers (Lee et al., 
1990).
These findings are confirmed in part by Balleisen et al. (1985) 
who also report a positive correlation between fibrinogen levels and 
age, smoking, oral contraception and body weight. No correlation was 
found with either menopausal status or alcohol consumption.
It is now widely accepted that increased fibrinogen levels play 
an important role in the development of CVD. It is also evident that 
environmental factors such as smoking, age, oral contraception and 
diet have a pronounced effect on fibrinogen levels and that these 
levels correlate positively with the risk of CVD. Even if raised 
fibrinogen levels are simply an indication of arterial damage an 
increase in fibrinogen concentration could still play a role in 
determining the thrombotic process proceeding the clinical event.
1.5 Fibrinogen Association with Peripheral Vascular Disease
Intermittent Claudication (IC) is the most common presentation 
of peripheral arterial disease (PAD). IC rarely causes tissue 
degeneration unless complicated by other factors such as advancing 
age, previous arterial obstruction, poor cardiac output or some 
metabolic or neurological complication, as in diabetes. The risk of 
coronary artery disease is much higher in patients with IC than in the 
general population (Hughson et al., 1978; Kannel and Shurtleff, 1971)
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resulting in an increased risk of mortality (Kannel et al., 1984, 
1985).
Smoking has been shown to be the strongest determinant in the 
development of IC (Hughson et al., 1978; Fowkes, 1989; Kannel et al., 
1984, 1985) and claudicants who smoke run a much higher risk of dying
during follow-up than non-smokers (Reunanen et al., 1982). Smoking is 
associated with severe atherosclerosis of the abdominal aorta which is 
associated with a much greater risk of aortic aneurysm and PVD 
(McGill, 1988). For example, Auerbach and Garfinkel, (1980) found that 
aortic aneurysms, involving the abdominal aorta, were eight times more 
common in smokers than in non smokers.
Fibrinogen has been shown to be a associated with IC (Hughson et 
al., 1978). Raised fibrinogen concentrations are associated with an 
increased blood viscosity, resulting in diminished tissue perfusion 
which could, therefore, contribute toward the symptoms of IC 
(Dintenfass et al., 1966). In 1973 Dormandy et al. studied 126 
patients with IC and found that blood viscosity was significantly 
raised compared to the age-matched, normal controls, with raised 
plasma fibrinogen being the most common single biochemical 
abnormality. In this study 33 patients had definite evidence of IHD as 
well as peripheral arterial disease (PAD) and had significantly higher 
basal blood viscosity than those with PAD alone. 62 of the patients in 
this study were followed up over a period of 1-3 years to assess the 
prognostic significance of the clinical and laboratory findings 
(Dormandy et al., 1973b). A significant correlation was found between 
the initial plasma fibrinogen levels and progress. In the patients who 
improved the mean initial plasma fibrinogen was within normal limits
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(<4g/L), whereas in patients who deteriorated the mean initia plasma 
fibrinogen was almost double the normal mean. Further evidence to 
support the role of fibrinogen as an important risk factor for PAD has 
been provided by Powell et al. (1987) and Baxter et al. (1988).
Powell et al. (1987) assessed asymptomatic arterial disease in 
100 males and found that the mean plasma fibrinogen concentration in 
patients with asymptomatic arterial disease was similar to patients 
with symptomatic arterial disease. Amongst these patients the 
continuing smokers were found to have a poorer prognosis and an 
increased fibrinogen level. In 1988 Baxter et al. screened 100 men for 
asymptomatic peripheral arterial disease and found 15% to be affected. 
They all had an increased concentration of plasma fibrinogen compared 
with men having no evidence of arterial disease.
Smoking has been shown to be the major determining factor in the 
progression of PAD as well as the main enviromental cause for 
increasing fibrinogen levels. Fibrinogen levels have also been shown 
to rise depending upon the severity of the disease. This suggests that 
fibrinogen may be an important risk factor for the development and 
progression of PAD.
1.6 Fibrinogen Association with Hypertension
Increased plasma fibrinogen concentration and plasma viscosity 
in hypertensive patients are well known phenomena. Harris and 
McLoughlin (1930) recorded abnormally increased blood viscosity in 
untreated hypertensive patients and these results have since been 
confirmed by Tibblin et al. (1966), Sonkodi et al. (1979), Letcher et 
al. (1981) Kannel et al., 1987 and Koenig et al. (1989).
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Fibrinogen, which is one determinant of plasma viscosity, has 
consistently been found to be elevated in hypertensive individuals. 
Sonkodi et al. (1979) were able to demonstrate that fibrinogen levels 
were significantly raised in 44 hypertensive patients compared to a 
control group. This has been confirmed by Letcher et al. (1981) who 
recorded abnormally high blood viscosity in untreated hypertensives 
and were able to demonstrate a direct relationship with fibrinogen 
levels, even in haematocrit-matched patients. Increased fibrinogen 
concentrations as well as fibrin degradation products have also been 
observed in patients with malignant hypertension (Garvas et al., 1975; 
Sonkodi et al., 1979). These observations have been substantiated by 
the work of Beatriz et al. (1989) who showed that the development of 
malignant hypertension was either directly or indirectly associated 
with the appearance of high levels of cross-linked forms of 
fibrinogen.
Other authors have shown that high fibrinogen levels in 
conjunction with high blood pressure may lead to an increased risk of 
CVD. The results of a study by Wilhelmsen et al. (1984) indicate an 
increased risk of stroke due to the synergistic interaction of blood 
pressure and fibrinogen and Stone et al. (1985) found that the 
incidence of heart attack in men with high systolic blood pressure was 
twelve times greater in those with high plasma fibrinogen levels than 
in those with low fibrinogen levels.
The two major factors which determine arterial blood pressure 
are cardiac output and resistance to blood flow (Pickering, 1936; 
Chien 1977; Guyton, 1980). The degree of resistance to blood flow is 
in turn determined by the diameter of the blood vessels and blood
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viscosity (Scholz, 1975). The associations found between plasma
fibrinogen levels, blood pressure and plasma viscosity indicate that
increases in plasma fibrinogen concentration cause an increase in 
blood viscosity and, therefore, might play a key role in the early 
phase of the development of hypertension.
1.7 Fibrinogen Genotyping-Association Studies
Three recent studies have suggested that genetic factors are
important in determining plasma fibrinogen levels. Hamsten et al. 
(1987) studied the relative importance of genetic and cultural factors 
in influencing fibrinogen levels in nuclear families. The study 
consisted of 85 families, identified by means of a proband with early 
myocardial infarction, and 85 families randomly selected from the 
general population. The results suggested that 51% of the variance of 
plasma fibrinogen levels is genetically determined and that cultural 
heritability had little if any effect.
Humphries et al. (1987) carried out an RFLP analysis on 91 
healthy individuals from North-West London for the Bell polymorphism 
at the beta fibrinogen gene locus and the TaqI polymorphism at the 
alpha fibrinogen gene locus. From this study it was estimated that 
genetic variation associated with the TaqI and Bell polymorphisms 
contributed 4.2% and 9.0%, respectively, of the total phenotypic 
variance in fibrinogen levels. This work was extended in 1991 by 
Thomas et al. who discovered a new polymorphism, 453bp from the start 
of transcription of the beta gene, with the enzyme Hae III. They used 
this polymorphism to analyse a group of 292 healthy men aged 45-69 
years. The group was divided into 120 smokers and 172 non-smokers. A 
significant association was found between fibrinogen levels and
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genotype in both the smokers and non smokers. As a result of this
study it was estimated that genetic variation associated with the
P
Haelll polymo^hism accounted for 3.1% of the variance in fibrinogen 
levels.
The findings of Humphries et al.(1987) and Hamsten et al.(1987) 
were not confirmed in a Norwegian study. Berg and Kierulf (1989) 
looked at 178 healthy unrelated individuals recruited from monozygotic 
twins and their families. Gene frequencies and mean fibrinogen 
concentrations reported by Berg and Kierulf (1989) are similar to 
those reported by Humphries et al. (1987). There was, however, no 
association between plasma fibrinogen concentrations and any genotype 
in either of the two fibrinogen polymorphisms examined. Furthermore 
the heritability of fibrinogen levels, calculated using the intraclass 
correlation coefficient in monozygotic twin pairs, indicated a lower 
level of heritability than that estimated by Hamsten et al., (1987).
Thus at the time this study was initiated the role of genetic 
variation at the fibrinogen loci in relation to plasma fibrnogen 
levels was controversial.
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1.8 AIMS
The present study was thus undertaken to address the controversy with 
regard to the genetic determination of fibrinogen levels by variation 
at the fibrinogen loci; to seek an association between the occurrence 
of intermittent claudication and fibrinogen genotype; and to seek an 
association between the predisposition to high or low blood pressure 
and the fibrinogen genotype. Specific aims within this framework were:
(1) to determine allele and haplotype frequencies at the 
alpha, beta and gamma fibrinogen loci in Scottish 
individuals.
(2) to seek linkage disequilibrium between the alpha, beta 
and gamma fibrinogen loci
(3) to correlate plasma levels of fibrinogen with various 
fibrinogen alleles/haplotypes
(4) to determine allele frequencies at the beta fibrinogen 
loci in individuals with contrasting predisposition to 
high blood pressure.
(5) to determine allele and haplotype frequencies at the 
fibrinogen loci in patients with intermittent 
claudication and matched controls.
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2.0 PATIENTS AND METHODS
2.1 Materials
A list of materials and stock solutions is presented in 
Appendix 1. All chemicals used were Analar grade and purchased from 
BDH limited. Restriction endonucleases and the 1Kb ladder were 
purchased from BRL Life Technologies Inc. Random primed DNA labelling 
kits were purchased from Boehringer Mannheim Ltd; Hybond-N filters and 
p3 2 isotope from Amersham Ltd and reagents for the polymerase chain 
reaction from Perkin Elmer-Cetus.
2.2 Recruitment of Cases and Controls with Peripheral Vascular 
Disease
2.2.1 Study Population
In a cross-sectional study of peripheral arterial disease in 
Edinburgh; nearly 1600 subjects aged 55-74 years were selected by age 
and sex stratified sampling from registers of 10 general 
practitioners. Peripheral arterial disease has been measured in all 
subjects by means of a WHO questionaire for intermittent claudication 
(Rose, 1962), Doppler ankle pressure (Carter, 1968) and reactive 
hyperaemia test (Fowkes et al., 1988). In this study, cases and 
controls were selected from this community sample of 1600 subjects.
2.2.2 Sample Recruitment
Cases and controls were selected from the data base of 1600 
subjects. After permission had been obtained from the subjects general 
practitioner those selected were invited by letter to attend the
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Peripheral Vascular Clinic at Edinburgh Royal Infirmary. Non­
responders were followed up by letter or telephone and 294 subjects 
were recruited for this study of which 152 were controls and 142 were 
patients.
Confirmation of the subject status as a case or control was 
obtained by repeat administration of the WHO questionaire on angina 
and intermittent claudication (Rose, 1962) and measurment of ankle and 
brachial systolic pressure using a Hawksley random zero 
sphygmomanometer and Doppler probe.
A questionaire on smoking was also repeatedly readministered 
although smoking histories were not matched. However, on the basis of 
interim results of a community study of 1000 subjects it would be 
expected that, of the cases recruited here, 37% will smoke cigarettes 
and 39% will be ex-smokers. Of the controls 23% will be smokers and 
30% will be ex-smokers.
2.2.3 Case Selection
Case selection included all subjects with (i) intermittent 
claudication according to WHO questionaire. Specificity is 98% (Criqui 
et al., 1985) and/or (ii) ankle/brachial systolic ratio of <0.8 in at 
least one leg. Traditionally 0.9 is taken as the cut off point in 
hospital studies and is over 95% specific (Carter, 1968). Individuals 
were excluded from the study if they had previous arterial surgery, 
rest pain, ulcer or gangrene.
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2.2.4 Control Selection
The controls were as closely age and sex matched to the cases 
as possible and were selected according to the following parameters 
(i) were shown to be free of all cardiovascular diseases (ii) to have 
an ankle/branchial systolic ratio of >1.0 in both legs (ill) to have a 
reactive hyperaemic ankle brachial ratio above the lowest 20% of the 
population distribution.
2.2.5 Laboratory Procedures
Fibrinogen genotyping was carried out by the author in the 
Duncan Guthrie Institute, Glasgow using gene probes provided by Dr. SE 
Humphries, Charing Cross Sunley Research Centre.
The following haemostatic factors were measured: fibrinogen by 
(three methods: nephelometric, clotting and immunological); cross- 
linked fibrin degradation products. Von Willebrand factor antigen, 
plasminogen activator inhibitor and B-Thromboglobulin. These assays 
were carried out by collègues at Edinburgh Royal Infirmary and the 
Royal Infirmary Glasgow.
2.3 Recruitment of Cases and Controls with Hypertension
2.3.1 Phase I
The aim of the Ladywell study is to identify those individuals 
most likely and those least likely to develop high blood pressure by 
the analysis of genetic, physiological and biochemical 
characteristics.
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In 1979 6088 adults, aged 35-64yrs and representing 76% of all 
adults in this age group, were selected from 24000 individuals 
registered at the Ladywell medical centre, Edinburgh and screened in 
order to identify subjects for the MRC mild hypertension trial.
All participants were identified via systematic selection from 
age/ sex registers and patients on treatment for hypertension were 
included. 1809 husband/wife pairs were screened, with each person 
being given an age/sex adjusted blood pressure and parental blood 
pressures were combined to identify high/high and low/low families. 
Blood pressure was measured twice using a random zero sph^imanometer 
and a standard adult cuff size. Diastolic blood pressures were 
recorded to the nearest 2mm Hg, after sitting for at least 10 minutes.
In 1986 the practice registers were reviewed. Of the original 
1809 couples, 1473 were still resident in the Ladywell catchment area. 
Letters were sent to each couple asking for the dates of birth and 
current addresses of offspring. 2879 offspring were identified, of 
whom 1169 were natural offspring to both parents and were aged between 
16-24 on 31-5-1986.
Offspring were invited to the medical centre where their blood 
pressure, pulse, height and weight were recorded. They were asked to
complete questionnaires requesting information on age, sex, marital
status, educational attainment, place of residence, employment status, 
personal medical history, current medication, menarche, contraception, 
pregnancy, parental medical history, physical activity, cigarette 
smoking, health knowledge, alcohol consumption and Bortner score. 864
individuals took part. This marked the end of Phase I, which was
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completed in March 1987.
To enable a comparison to be made between the blood pressure
of parents and offspring a Z score was calculated for each person as
follows: the degree of deviation from the mean for each individual's 
age/sex group was calculated and divided by the standard deviation of 
blood pressures within the group. Individual scores and age-sex 
distributions were based on the arithmetic mean of all blood pressure 
data with two year age groups for the offspring and five year age
groups for the parents. The scores for women were based on roughly
equal numbers of those taking and not taking the oral contraceptive 
pill. Parents on treatment for hypertension were given Z scores 
corresponding to the mean score of the top 5% of the distribution of 
scores in their age and sex group. Using this approach 95% of scores
are within the range from +/-2. Four groups of offspring were
identified (Figure 2.1).
2.3.2 Phase II
Random samples were taken from the three largest groups in
order to identify 4 groups of approximately 70 individuals.
Statistical analysis allowed 238 offspring to be approached at the 
final stage, of which 201 participated. Height, weight, blood pressure 
were recorded again a non fasting blood sample was taken and a 24 hour 
urine sample was collected.
2.3.3 Phase III
One hundred of the 201 offspring took part in detailed 
biochemical and physiological studies.
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Figure 2.1. Offspring and parental Z scores identified by means of the four comers Approach. The 
offspring blood pressure scores are on the vertical axis with the parental on the horizontal axis. The 
scatter diagram was inspected to identify the score level which, when applied to both offspring and 
parental blood pressure would identify at least 70 offspring in each comer. It was found that a score 
+/- 0.35 identified the following number of offspring: A. Low parental, high offspring blood pressure 
122; B. High parental, high offspring blood pressure 118; C. Low parental, low offspring blood pressure 
164 and D. High parental, low offspring blood pressure 68.
2.3.4 Phase IV
Parents height, weight, blood pressure, pulse rate was 
measured and a blood sample was taken.
2.4 Preparation of Alpha, Beta and Gamma Fibrinogen Probes
The alpha, beta and gamma fibrinogen cDNAs were all cloned 
into the PstI site of pRT218 which is tetracycline resistant. Probes 
were grown up as follows:
2.4.1 Plasmid Preparation
10ml of L broth media containing O.Olmg/ml tetracycline was 
inoculated with a single bacterial colony and incubated at 37°C 
overnight with vigorous shaking. The following morning 25ml of L broth 
containing tetracycline was inoculated with 0.1ml of the overnight 
culture and incubated at 37*C with vigorous shaking until the culture 
reached its late log phase (OD at 600 nm approx 0.6). 500ml of L broth 
media with tetracycline was measured into a 2 litre flask and 
inoculated with the 25ml of late log culture. This was incubated for 
2.5hrs at 37°C with vigorous shaking (OD at 600nm approx 0.4). 2.5ml 
of a solution of chloroamphenicol (34mg/ml in ethanol) was then added 
and incubation continued overnight.
The 500ml culture was split evenly into 2x250ml centrifuge 
tubes and spun down at 7K for lOmin at 5°C. The supernatant was 
discarded and the cells resuspended in 25ml of 0.05M Tris-HCl pH8. The 
cell suspensions were then combined and transferred to a Borex tube 
and centrifuged at 9K for lOmin at 5°C. The supernatant was discarded 
and the cell pellet resuspended in 25ml of lysis mix containing 0.125g
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of freshly prepared lysosyme. This was placed on ice for 35min and 
stirred occasionally* The lysate was then transferred into a 250ml 
centrifuge tube to which 40ml of 0.2N NaOH/1% SDS was added and mixed 
until it became clear and then placed on ice for 5min. 20ml of 3M NaAc 
pH 4.8 was added and mixed and left on ice for 15min after which the 
solution was centrifuged at lOK for lOmin at 5°C. The supernatant was 
transferred into a fresh bottle and the pellet discarded. 0.6 volume 
of ice cold isopropanol was added to the supernatant which was 
centrifuged at lOK for lOmin at 5°C. The supernatant was discarded and 
50mls of ice cold ethanol (70%) was added to the pellet and mixed. 
This was then centrifuged at lOK for lOmin at 5*0. The ethanol was 
poured off and the DNA pellet allowed to air dry. Once dry the DNA was 
resuspended in 5ml of TE buffer.
2.4.2 Ethidium bromide-Caesium Chloride density Gradient 
Centrifugation
The resuspended DNA was removed to a universal containing 7.2g 
of ceasium chloride and made up to a final volume of 6.7ml with TE 
buffer. 700ul of ethidium bromide (5mg/ml) was then added and the 
mixture transferred to a Sorvall tube and overlayed with liquid 
paraffin. The tubes were sealed with an aluminium plug and screw in 
cover and any air bubbles removed by aspiration prior to sealing. 
These were then spun at 40,000rpm for a minimum of 40hrs at 20°C in 
a Sorvall Ultracentrifuge using a T.865.1 rotor.
DNA has a buoyant density of approximately 1.7g/cm®. The 
density gradient produced by centrifugation results in the migration 
of the DNA to a point in the gradient where the CsCl density is also 
l'7g/cm3. With the addition of ethidium bromide (EtBr) super coiled
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DNA can be separated from non super coiled molecules by its 
intercalation between adjacent base pairs, causing partial unwinding 
of the double helix. This unwinding results in a decrease in the 
buoyant density which causes super coiled molecules to band in an 
EtBr-CsCl gradient at a different position to linear and open circular 
DNA.
At the end of the spin the tubes were opened and the paraffin 
layer removed with a pipette. The super coiled DNA was collected with 
a Pasteur pipette and removed to a fresh tube. The EtBr bound to the 
plasmid DNA was extracted with isopropanol (500ul). This was done by 
gently mixing and removing the upper aqueous layer containing the 
EtBr. This process was repeated with the following exception: three
drops of water were added before the addition of the isopropanol to
prevent the ceasium chloride coming out of solution. Once the aqueous 
phase was seen to be clear i.e. all the ethidium bromide had been 
removed, the plasmid DNA was transferred to a freshly washed collodian 
bag. A needle was forced through the collodian bag about 8mm from the 
top. Dialysis was carried out overnight with de-ionised water to 
remove the ceasium chloride, and the plasmid stored at -20°C.
2.4.3 Releasing Insert from Plasmid.
62ul of plasmid was measured into a 0.5ml Eppendorf tube to
which 8ul of React 2 buffer, 4ul of spermidine, and 48 units (6ul) of
the restriction enzyme PstI were added. This was incubated overnight 
at 37®C. The released insert was resolved on a 1.2% low melting point 
(LMP) agarose gel (containing 3ul of EtBr) along with 20ul of 1Kb 
ladder at 120mA for 4hrs. The gel was then visualised over UV light. 
PstI digestion of pFAI (containing the alpha cDNA) gives a vector band
Page 24
of 4.7Kb and a band of 1.7Kb which is used as the probe. pFB5 (beta) 
gives bands of 4.7Kb (vector) and 1.4Kb (probe). pFGI (gamma) gives 
bands of 4.7Kb (vector) and two bands of 700bp and 250bp, the larger 
of which is used as the probe. Figure 2.2 represents an LMP gel on 
which the released probes were resolved. The required band was excised 
and removed to a previously weighed Starstedt tube. The Starstedt tube 
containing the insert was weighed and the weight of the insert 
derived. A volume of SDW 3 times the weight of the insert was added 
and the insert boiled for lOmin. This was frozen at -20°C until use.
2.5 Genomic DNA Extraction
Genomic DNA was extracted from Buffy coat samples (supplied by 
colleagues at Edinburgh University) using a method described by Millar 
et al. (1988).
30ml of ice cold lysis mix was added to 5ml of Buffy coat 
which was then centrifuged at 2.8k for lOmin at 4°C in a IEC DPR-6000 
centrifuge. The supernatant was discarded and the pellet resuspended 
in 3ml of nuclei lysis buffer to which 0.2ml of 10% SDS and 0.1ml of 
proteinase K were added. This was incubated at 37°C overnight.
After incubation, 1ml of 6M saturated NaCl was added and the 
mixture shaken vigorously for 15sec. An equal volume of 
phenol/chloroform mix was added and centrifuged at 2.5K for 15min at 
20°C. The top aqueous layer was then removed to a universal and the 
DNA precipitated by the addition of 2 volumes of ethanol. The 
precipitated DNA was spooled out and resuspended in a suitable volume 
of TE buffer and stored at 4oC or frozen at -20°C until use.
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Figure 2.2. Resolution of alpha, beta and gamma fibrinogen probes. The alpha probe (1.7Kb tracks 
1-3), gamma fibrinogen probe (0.7Kb tracks 5-7) and the beta Gbrinogen probe 1.45Kb (tracks 9-11) 
were resolved on 1.2% agarose gel containing 3/^ 1 of EtBr at 120mA for 4 hours. A  1Kb ladder (tracks 
4,8 and 12) was used to identify the required bands which were subsequently excised.
2.5.1 Digestion of Genomic DNA Using Restriction Enzymes
lOug of genomic DNA was used for each digestion and the 
concentrations of the extracted DNAs were calculated based on the O.D. 
of the samples at 260nm. The O.D. of a 1 in 100 dilution of each 
sample was measured in a dual beam spectrophotometer (LKB Biochem 
Ultrospec 4050) using a deuterium lamp.
Digests were set up using the appropriate restiction enzyme 
and incubated overnight at the recommended temperature (Table 2.1). 
Where a single restriction enzyme was used 4ul of the recommended 
reaction buffer, 2ul of O.IM spermidine and 3ul of restriction enzyme 
were added to lOug of DNA and made up to a final volume of 40ul with 
the appropriate volume of SDW. In the case of the KpnI/SacI digests 
6ul of reaction buffer, Sul of O.IM spermidine and 4ul of each enzyme 
were added and made up to a final volume of 60ul with SDW.
2.5.2 Agarose Gel Electrophoresis of Digests
Digests were resolved on 0.8% agarose gels containing 3ul of 
EtBr (lOmg/ml). Following addition of 6ul of loading mix, digests were 
loaded and run at 250mA for approximately 3hrs or at 70mA overnight. 
The gels were visualised on a U.V. transilluminator (316nm) and 
photographed with a Polaroid type 667 film in a Polaroid instant print 
camera fitted with a Kodak 22A Wratten filter.
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Table 2.1. The international units required for the three enzymes, TaqI, Bell and KpnI/SacI, to cut Ifig 
of DNA at the stipulated incubation temperature.
Enzyme Units/ul Incubation Temp
oC
Taql 10 65
Bell 10 60
Kpnl/Sacl 5/11 37
2.6 Southern Blotting
Gels were treated for 15min with 0.25M HCl with gentle 
agitation followed by a 30min wash in dénaturation solution and a 
30min wash in neutralisation solution. The gels were blotted overnight 
according to the standard Southern blotting procedure (Southern, 
1975). A tank was filled with lOxSSC. A wick was prepared by laying a 
double thickness of Whatman 3mm paper over a glass plate placed across 
the tank such that both ends of the 3mm paper were within the buffer. 
Once it was ensured that the wick was entirely wet and uniformly flat, 
the gel was placed on top of the wick. Hybond-N membrane, labelled and 
cut to size, was gently layed over the gel. Two sheets of 3mm paper 
(soaked in 2xSSC and cut to size) were layed on top of the membrane. 
Again care was taken to ensure that the membrane and 3mm paper were 
uniformly flat. The remaining area of wick was shrouded in plastic 
sheeting and a stack of paper hand towels, a glass plate and a small 
weight placed on top of the gel.
After overnight capillary action the blotting equipment was 
dismantled, the hybond filters were lifted off the gels and rinsed in 
2xSSC. The filters were baked between 2 sheets of 3mm paper for 4-5hrs 
in a hot air oven set at 80°C.
2.7 Autoradiography
2.7.1 Prehybridisation of Filters
After baking, the filters were sealed in a polythene bag 
containing 8ml of prehybridisation solution and 80ul of sonicated 
denatured Salmon sperm DNA (lOmg/ml; boiled for 10 min). The bags were 
incubated for at least 3hrs at 65°C (generally overnight)
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2.7.2 Oligonucleotide Labelling Technique
The alpha, beta and gamma fibrinogen probes were labelled 
using random primed DNA labelling kits. 22ul of probe was measured 
into a starstedt tube, boiled for lOmin and then incubated for 6min at 
37°C. 2ul of the oligonucleotides dATP, dGTP and dTTP, 3ul of SDW, 4ul 
of reaction mix, 2ul of Klenow enzyme and SOuCi of P®^  dCTP isotope 
(5ul) were then added to the denatured probe and the mixture incubated 
for l-1.5hrs at 37®C. The reaction was terminated by the addition of 
2ul of 0.5M EDTA.
2.7.3 Separation of Labelled from Unlabelled Probe
A column packed with Sephadex G50 equilibrated with lxSSC/0.1% 
SDS was prepared and topped up with IxSSC. The column was allowed to 
settle so that the Sephadex G50 was 4mm below the top. The IxSSC was
removed before addition of the probe. Once the probe had been added
the bung sealing the base of the column was removed and the probe
allowed to run into the column before the addition of more IxSSC. The
base of the column was monitored and the first peak (> 200cpm) 
corresponding to the labelled probe was collected in a Sarstedt tube 
(approximately 0.5ml). The column was then monitored for the second 
peak which corresponds to the unlabelled probe the presence of which 
indicates successful separation of the labelled from the unlabelled 
probe.
2.7.4 Hybridisation of Filters
The collected probe was boiled for lOmin and placed on ice for 
2min and then added directly to the filters in the polythene bag, 
ensuring that no air bubbles were trapped when resealing the bag. 
Hybridisation of the probe to the filters was carried out overnight at
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65°C.
2.7.5 Washing Filters
Excess probe was removed by washing the hybridised filters in 
2xSSC/0.1% SDS at room temperature for 20 minutes. Filters were washed 
sequentially in solutions of increasing stringency for 20-30 min each, 
as required; lxSSC/0.1% SDS (room temperature), lxSSC/0.1% SDS (65®C), 
0.5xSSC/0.1% SDS (65*0), 0.lxSSC/0.1%SDS (65°C), 0.05xSSC/0.1% SDS
(65°C). The strength of the signal was measured between washes with a 
Seris 900 mini monitor until the signal was below lOcps.
2.7.6 Producing an Autoradiograph
The filters were placed in a light-tight cassette containing 
intensifying screens with Kodak X-OMAT AR diagnostic film and put down 
at -70°C for an overnight exposure. The film was then developed in a 
Fuji RG-11 X-ray film processor. When the band was too faint, filters
were put down with fresh film and exposure time increased.
2.7.7 Stripping of Filters
Some of the filters were stripped and reprobed. 0.4M NaOH was
added to the filters and then incubated at 42*C for 30min. This was
followed by treatment with neutralisation solution at room temperature 
for 30min. The filter was then rinsed in 2XSSC and blotted dry ready 
for prehybridisation and was stored until required.
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2.8 DNA Amplification by the Polymerase Chain Reaction (PGR)
A specific 1.3Kb region of DNA at the beta fibrinogen locus, 
as defined by the oligonucleotide primers 766L (5*-CTC CTC ATT GTC GTT 
GAG ACC TTG GGA C-3*) and 767L (5*-AAG AAT TTG GGA ATG CAA TCT CTG CTA 
CCT-3*), was amplified by PCR (Figure 2.3). A 50ul reaction was set up 
for each DNA sample. 5ul of dNTPs (2mM), 5ul of lOx reaction buffer, 
250ng (O.Sul) of 766L primer, 250ng (O.Sul) of 767L primer, a 
previously determined volume of distilled water, lug of genomic DNA 
and 2.5iu (O.Sul) of Taq polymerase (Ampli-Taq) were measured into a 
0.5ml Eppendorf tube. The primers were denatured at 93°C for 3.0min, 
annealed at 55°C for l.Omin and extended at 72°C for 2.0min for 1 
cycle. The primers were then denatured at 93°C for l.Omin annealed at 
55°C for l.Omin and extended at 72°C for 2.0min for 30 cycles in a 
Perkin Elmer-Cetus thermocycler 480.
2.8.1 PCR Control
2.8.1.1 Negative Control
An aliquot of reaction mixture containing everything except 
DNA was subjected to PCR with each batch of amplified DNA. Resolution 
of bands, in the negative control, by electrophoresis indicates the 
presence of contaminating bacterial or viral DNA.
2.8.2 Check Gel
To check the efficiency of the PCR reaction, 2ul of loading 
mix was added to lOul of each of the PCR products which were then 
loaded and run with 20ul of a 1Kb ladder on a 1.4% SeaKem agarose gel 
(containing 3ul EtBr) in 0.5x TEE, at 100mA for approximately 30min.
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2.9 Digestion of DNA with HaelII
The PCR product of DNA samples which were proven to have been 
amplified; i.e. a 1.3Kb band was seen on the check gel, were incubated 
with the restriction endonuclease Haelll. Eight iu. (3ul) of Haelll 
and 4ul of React 2 buffer were added to 50ul of the PCR products which 
were then placed in a 37°C water bath for a minimum of 4hrs. Haelll 
cuts the 1.3Kb PCR product to give polymorphic bands of 958 or 575 and 
383bp. A constant band of 343bp is also detected.
2.9.1 Electrophoresis of the Haelll Digests
The Haelll digests were run on a 1.4% SeaKem agarose gel 
(containing 3ul EtBr) in 0.5xTBE buffer. 6ul of loading mix was added 
to 50ul of the digest products. The samples were loaded and run with 
20ul of a 1Kb ladder at 100mA until the loading mix reached the bottom 
third of the gel.
2.9.2 Molecular Weight Marker
The 1.3Kb band, the 958bp band, the 575bp band, the 383bp band 
and the 343bp band were sized using the BRL 1Kb ladder which has 
approximate molecular weights of 0.5, 1, 1.6, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, and 12Kb.
2.9.3 Visualising the Gels
The gels were visualised and photographed as stated in Section
2.5.2.
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2.10 Statistical Methods
Gene frequencies were calculated by gene counting. Chi-square 
(X%) analysis using Yates correction (Equation 1) was applied for 
comparison between allele frequencies reported here and those reported 
by Humphries et al, (1987) and Berg and Kierulf (1989); to compare 
alternative allele frequencies between cases and controls and for 
assesment of linkage disequilibrium.
Equation 1.
S X2 = [( Obs-Exp )-0.5]2 
Exp
Where:Obs = Observed numbers 
Exp = Expected numbers 
0.5 = Yates correction
Analysis was carried out to test for linkage disequilibrium 
between the alleles of the Taql and Bell RFLPs; Taql and KpnI/SacI 
RFLPs; and Bell and KpnI/SacI RFLPs using the standardised 
disequilibrium coefficient (delta value) (Equation 2). Delta values 
were calculated according to Chakravarti et al. (1984) and probability 
(p) values were calculated according to Fishers exact probabilities 
(Equation 3).
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Equation 2.
Delta = glg4-g2g3
/(gi+g2)(g3+g4)(gi+g3)(g2+g4)
Where:gi=ni/n(i=l...,4) and ni, nz, na and n4 are the numbers of ++, 
+-, -+, and —  haplotypes observed in a sample of n chromosomes. Delta 
is the correlation coefficient between the uniting gametes at the two 
loci and is independent of the true gene frequencies of the RFLPs.
Equation 3.
p = 2 ( ni +nz ) ! ( na +n4 ) ! ( ni +na ) ! ( nz +n4 ) !
n!ni!nz!na!n4!
Where:! denotes factorials and means successive multiplication by 
cardinal numbers in descending series.
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3.0 RESULTS
3.1 The Alpha, Beta and Gamma Fibrinogen Gene RFLPs
The common and rare alleles detected by fibrinogen gene probes 
for the alpha, beta and gamma fibrinogen loci with the respective 
enzymes Taql, Bell and KpnI/SacI are designated A and a, B and b and D 
and d and these are illustrated in Figure 3.1. The common and rare 
alleles detected by the restriction enzyme Haelll at the beta 
fibrinogen locus are designated HI and H2 and are illustrated in 
Figure 3.2.
A total of 235 genomic DNA samples (115 cases and 120 
controls) in the peripheral vascular disease project were extracted 
and analysed with respect to the Taql and KpnI/SacI gene rated RFLPs 
in the alpha and gamma fibrinogen loci. Of these individuals 114 cases 
and 119 controls were genotyped with respect to the Bell generated 
RFLP at the beta fibrinogen locus. These results are presented in 
Appendix 2. A further 170 of these samples were genotyped with respect 
to the Haelll polymorphism at the beta fibrinogen locus the results of 
which are presented in Appendix 3.
3.1.1 Overall Genotype frequencies
Gene frequencies were calculated from inspection of the data 
in Appendices 2 and 3. For the Taql/alpha cDNA fibrinogen polymorphism 
allele relative frequencies were 0.75 (for A the 2.4Kb fragment) and 
0.25 (for a the 1.6Kb fragment). The Bcll/beta cDNA fibrinogen 
polymorphism allele relative frequencies were 0.85 (for B the 5.3Kb 
fragment) and 0.15 (for b the 0.15Kb fragment). The KpnI/SacI cDNA
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(A) 2.4Kb
(a) 1.6Kb 
(constant) 0.7Kb
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(constant) 6.6Kb
(B) 5.3Kb
(b) 4.2Kb
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(c)
(d) 14Kb 
(D) 11Kb i
Figure 3.1 a) Taql polymorphism detected by fibrinogen a cDNA probe. The polymorphic 
bands are 2.4Kb (A) and 1.6Kb (a) w ith a 0.7Kb constant band.
b) Bell polymorphism detected by fibringogen B cDNA probe. The polymorphic 
bands are 5.3Kb (B) and 4.2Kb (b) w ith a 6.6Kb constant band.
c) KpnI/SacI polymorphism detected by fibrinogen y cDNA probe. The polymorphic 
bands are 11Kb (D) and 14Kb (d).
958bp
5 7 5 b p
3 8 3 b p
3 4 3 b p
H1H2 H1H1 H1H2 H1H1 H2H2 H1H1
Figure 3.2 Beta Fibrinogen Gene RFLPs Detected by the Restriction Enzyme Haelll. The polymerase 
chain rcacion (PCR) was used to amplify a specific 1.3Kb region o f DNA upstream o f the start o f 
transcription of the beta Gbrinogen gene. Restriction digests of the 1.3Kb PCR product produces the 
following band sizes; 575bp, 383bp (H I) and 958bp (H2) with a 343bp constant band.
fibrinogen polymorphism allele relative frequencies were 0.76 (for D 
the 11Kb fragment) and 0.24 (for d the 14Kb fragment) and the 
Haelll/beta fibrinogen polymorphism allele frequencies were 0.82 (for 
HI the 575bp and 383bp fragments) and 0.18 (for H2 the 958bp 
fragment).
The overall genotype frequencies were compared with those 
predicted from the Hardy-Weinberg equilibrium and no significant 
differences were noted (Table 3.1). The genotype frequencies for cases 
and controls were similarily treated and again no significant 
differences were observed (Table 3.2).
3.2 Linkage Disequilibrium
and the standardised disequilibrium coefficient (delta 
value) were calculated to test the null hypothesis that there was no 
association between the Taql/alpha and Bcll/beta, the Bcll/beta and 
KpnI/SacI/gamma, the Taql/alpha and KpnI/Sad/gamma and the Bcll/beta 
and Haelll/beta markers. The null hypothesis was rejected for all four 
combinations. X^, delta and p-values are presented in Table 3.3 and 
indicate strong linkage disequilibrium between the Taql/alpha and 
Kpnl/Sad/gamma markers and the Bcll/beta and HaellI/beta markers 
(p=l.1x10-27 and 2.24x10-* respectively). A lesser association was 
found between the alpha/TaqI and beta/BclI loci (p=6.6xlO-*); 
beta/BclI and gamma/Kpnl/SacI markers (p=2.5x10-*); alpha/TaqI and 
beta/Haelll (p=1.3xlO-*) markers and the gamma/KpnI/SacI and 
beta/Haelll markers (p=1.4xlO-*).
Page 35
Table 3.1 Comparison o f observed and expected numbers o f persons in the peripheral vascular disease 
study of different Fibrinogen genotypes for the Taql, Bell, KpnI/SacI and H aelll polymorphisms 
assuming Hardy-Weinberg equilibrium. Where 1=A, B, D or H I and 2= a, b, d or H2.
Taql Bell KpnI/SacI H aelll
Genotypes
Obs. Exp. Obs. Exp. Obs. Exp. Obs. Exp.
1-1 133 132.2 168 168.3 136 135.7 117 114
1-2 87 88.1 59 59.4 86 85.7 46 50
2-2 15 14.7 6 5.2 13 13.5 7 6
X'=0.025 (NS) X^=0.020 (NS) X"=0.126 (NS) X^ = 0.3 (NS)
Table 3.2 À comparison of observed and expected numbers of persons with different genotypes for
the case and control groups of the peripheral vascular disease study for the Taql, Bell and KpnI/SacI
polymorphisms at the alpha, beta and gamma fibrinogen loci assuming Hardy-Weinberg equilbrium.
Genotypes Cases Controls
Obs .No Exp.No. Obs .No. Exp. No.
A A  64 66 71 68
Aa 47 42 38 45
aa 4 7 11 7
X^=1.41 (NS) X^=2.74 (NS)
BB 74 73 97 96
Bb 35 36 21 22
bb 5 5 1 1
X^=0.06 (NS) X^=0.06 (NS)
DD 68 70 71 69
Dd 43 39 40 44
dd 4 6 9 7
H iH i 52 52 61 61
H 1H2 24 24 20 20
H2H2 3 3 2 2
X^ = 0.00 (NS) X? = 0.00 (NS)
Table 3.3. Chi-square (X^), the standardised disequilibrium coefficient (A) and p-values from the 
analysis o f linkage disequilibrium/equilibrium between the alpha, beta and gamma loci.
Comparison X" Delta value p value
p-BclI/a-TaqI 4.06 (NS) -0.1423 6.6 X 10"*
P-BclI/y-Kpnl/SacI 2.03 (NS) -0.1450 2.5 X 10 ^
a-T aql/y-Kpnl/SacI 358.08 (S) 0.6981 1.1 X 10-2^
p-Haelll/p-BclI 106.61 (S) 0.462 2.2 X 10^
P-Haelll/a-TaqI 4.49 (NS) -0.174 1.3 X 10'^
P-Haelll/y-Taql 5.77 (NS) -0.188 1.4 X 10"*
NS = not significant 
S = significant
3.3 Relationship of fibrinogen level to genotype
Fibrinogen levels were determined in the peripheral vascular 
disease case/control study by clotting (Clauss, 1957) or nephelometric 
assays (Stone et al., 1970) and the results are presented in Tables 
3.4-3.7 for cases and controls separately/combined and with/without 
correction for age, sex and smoking history. None of the three DNA 
markers Taql/alpha, Bcll/beta, Kpnl/Sad/gamma showed any 
statistically significant association with fibrinogen level in this 
study.
The 235 individuals in this study, analysed for the markers 
Taql/alpha Bcll/beta and Kpnl/Sad/gamma had one of 13 different 
haplotypes. The 13 haplotypes are listed in Table 3.8 where the 
distribution of each haplotype between the cases and controls is 
indicated. An overall comparison of the difference in haplotype 
distribution between cases and controls was not statistically 
significant. Considered individually haplotypes 3, 4, 5 and 7 were 
more predominant in cases than controls with the difference in 
distribution of haplotye 5 reached statistical significance.
In Tables 3.9-3.12 the haplotypes for the Taql/alpha, 
Bcll/beta and Kpnl/Sad/gamma markers recorded in this study are 
presented together with fibrinogen levels, using the clotting method 
or nepholometric methods with and without adjustment for age, sex and 
smoking habit.
No statistically significant association was detected for any 
of these haplotypes in respect of fibrinogen levels. The percentage of 
phenotypic variability in Tables 3.9-3.12 was calculated using the
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Table 3.4. The mean fibrinogen levels and genotypes recorded in the peripheral vascular disease study.
Fibrinogen levels were measured by the clotting method for cases and controls separately and combined.
Values given here are unadjusted for age, sex and smoking.
Genotype
Mean Fibrinogen level (95% Cl) 
Controls Cases Total
AA 2.76 (2.63,2.90) 3.07 (2.91,3.24) 2.90 (2.79,3.01)
Aa 2.73 (2.50,2.98) 3.25 (3.03,3.49) 3.01 (2.84,3.19)
aa 2.72 (2.41,3.06) 3.48 (1.79,6.72) 2.86 (2.53,324)
p-value 0.95 0.30 0.48
BB 2.73 (2.61,2.85) 3.16 (2.99,3.34) 2.90 (2.80,3.01)
Bb 2.89 (2.60,3.22) 3.17 (2.94,3.43) 3.07 (2.88,3.26)
bb 2.19 2.97 (2.13,4.14) 2.82 (2.13,3.74)
p-value 0.33 0.82 0.29
dd 2.74 (2.39,3.14) 3.48 (1.80,6.72) 2.91 (2.53,3.34)
Dd 2.61 (2.44,2.79) 3.29 (3.06,3.53) 2.94 (2.79,3.11)
DD 2.83 (2.67,2.99) 3.06 (2.90,3.23) 2.94 (2.82,3.05)
p-value 0.21 0.20 0.99
Table 3.5. The mean fibrinogen levels and genotypes recorded in the peripheral vascular disease study.
Fibrinogen levels were measured by the nephelometric method for cases controlled separately and
combined. Values given are unadjusted for age, sex and smoking.
Genotype
Mean Fibrinogen level (95% Q ) 
Controls Cases Total
AA 3.90 (3.71,4.09) 4.27 (4.06,4.49) 4.07 (3.93,4.21)
Aa 3.84 (3.51,4.17) 4.74 (4.44,5.03) 4.33 (4.07,4.57)
aa 4.15 (3.33,4.78) 4.77 (3.70,5.84) 4.32 (3.70,4.94)
p-value 0.61 0.03 0.13
BB 3.84 (3.66,4.03) 4.51 (4.28,4.73) 4.12 (3.97,4.27)
Bb 4.21 (3.81,4.61) 4.42 (4.09,4.75) 4.34 (4.09,4.59)
bb 3.84 4.56 (3.78,5.34) 4.44 (3.77,5.11)
p-value 0.24 0.89 0.26
dd 4.26 (3.26,5.26) 3.01 (2.89,3.13) 4.42 (3.73,5.11)
Dd 3.69 (3.44,3.94) 2.95 (2.75,3.14) 4.28 (4.05,4.51)
DD 3.98 (3.77,4.19) 3.00 (2.63,3.37) 4.10 (3.95,4.25)
p-value 0.12 0.82 0.27
Table 3.6. The mean fibrinogen levels and genotypes recorded in the peripheral vascular disease study.
Fibrinogen levels were measured by the clotting method for cases and controls separately and combined.
Values presented here are adjusted for age, sex and smoking.
Genotype
Mean Fibrinogen level (95% Cl) 
Controls Cases Total
AA 2.86 (2.81,2.90) 3.03 (2.97,3.08) 2.94 (2.90,2.97)
Aa 2.82 (2.76,2.89) 3.03 (3.54,3.09) 2.94 (2.89,2.98)
aa 2.87 (2.76,2.99) 3.00 (2.59,3.49) 2.90 (2.80,3.00)
p-value 0.57 0.97 0.83
BB 2.86 (2.82,2.89) 3.04 (2.99,3.09) 2.94 (2.90,2.97)
Bb 2.78 (2.70,2.87) 3.00 (2.93,3.07) 2.91 (2.86,2.98)
bb 2.92 3.01 (2.80,3.24) 2.99 (2.83,3.17)
p-value 0.24 0.55 0.67
dd 2.89 (2.75,3.03 3.01 (2.59,3.49) 2.92 (2.80,3.04)
Dd 2.80 (2.74,2.86) 3.06 (3.01,3.11) 2.93 (2.88,2.78)
DD 2.87 (2.83,2.91) 3.01 (2.96,3.06) 2.94 (2.90,2.97)
p-value 0.14 0.44 0.94
Table 3.7. The mean fibrinogen levels and genotypes recorded in the peripheral vascular disease study.
Fibrinogen levels were measured by the nephelometric method for cases and controls separately and
combined. Values presented here are adjusted for age, sex and smoking.
Genotype
Mean Fibrinogen level (95% Cl) 
Controls Cases Total
A A 4.08 (4.01,4.15) 4.30 (4.22,4.38) 4.19 (4.13,4.24)
Aa 4.05 (3.95,4.15) 4.32 (4.23,4.40) 4.20 (4.13,4.27)
aa 4.12 (3.96,4.28) 4.30 (3.81,4.80) 4.17 (4.03,4.32)
p-value 0.72 0.98 0.95
BB 4.10 (4.04,4.15) 4.33 (4.26,4.41) 4.20 (4.15,4.25)
Bb 3.96 (3.82,4.08) 4.26 (4.16,4.36) 4.15 (4.06,4.23)
bb 4.19 4.26 (3.94,4.57) 4.25 (4.00,4.48)
p-value 0.10 0.44 0.48
dd 4.14 (3.95,4.340 4.30 (3.81,4.80) 4.19 (4.03,4.36)
Dd 4.01 (3.72,4.10) 4.35 (4.28,4.43) 4.19 (4.12,4.26)
DD 4.10 (4.04,4.17) 4.28 (4.20,4.37) 4.19 (4.14,4.25)
p-value 0.20 0.52 0.99
{thru.
Table 3.8. The thirteen different haplotypei^ recorded in the peripheral vascular disease study and their
distribution between the cases and controls.
Haplotype Total Controls Cases p-value
1 (aa BB DD) 86 49 (57%) 37 (43%) 0.18
2 (Aa BB Dd) 55 50 (55%) 25 (45%) 0.56
3 (aa Bb DD) 37 16 (43%) 21 (57%) 0.30
4 (Aa BB DD) 10 4 (40%) 6 (60%) 0.47
5 (Aa Bb Dd) 16 4 (25%) 12 (75%) 0.03
6 (AA BB dd) 12 8 (67%) 4 (33%) 0.27
7 (aa bb DD) 4 1 (25%) 3 (75%) 0.73
8 (aa BB Dd) 6 4 (67%) 2 (33%) -
9 (AA Bb dd) 1 1 (100%) 0 -
10 (Aa Bb DD) 1 0 1 (100%) -
11 (aa Bb Dd) 1 0 1 (100%) -
12 (AA BB Dd) 2 2 (100%) 0 -
13 (Aa bb Dd) 2 0 2 (100%) -
A/-LP
Table 3.9. The mean clottable fibrinogen levels and the 13 haplotypes^n the peripheral vascular disease 
study. Values presented here are adjusted for age, sex and smoking. A  one way analysis o f variance 
(ANOVA) gave a p-value o f 0.94. A  between group variablity o f 0% and a phenotypic variability of 
2.4% were recorded.
Haplotype Mean Fibrinogen Level (95% Cl) Total Relative Frequency
1 2.94 (2.90, 2.99) 81 0.368
2 2.93 (2.87, 3.00) 52 0.236
3 2.91 (2.83, 2.99) 34 0.155
4 2.91 (2.80, 3.03) 10 0.045
5 2.93 (2.84, 3.02) 15 0.068
6 2.94 (2.82, 3.06) 11 0.05
7 2.98 (2.67, 3.33) 4 0.018
8 2.89 (2.66, 3.15) 6 0.027
9 2.67 1 0.0045
10 3.17 1 0.0045
11 3.06 1 0.0045
12 2.81 (2.18, 3.62) 2 0.009
13 3.01 (2.76, 3.30) 2 0.009
Total 2.93 (2.91, 2.96) 220
(ik^
Table 3.10 The mean clottable fibrinogen levels and the 13 haplotypes/in the peripheral vascular 
disease study. Values presented here are unadjusted for age, sex and smoking. One way analysis o f 
variance (ANOVA) gave a p-value of 0.31. A  between group variability o f 0.6% and phenotypic 
variance o f 4.9% were recorded.
Haplotype Mean Fibrinogen level (95% Cl) Total Relative Frequency
1 2.89 (2.76, 3.02) 82 0.366
2 2.89 (2.69, 3.20) 53 0.237
3 2.99 (2.77, 3.22) 35 0.156
4 3.29 (2.57, 4.21) 10 0.045
5 3.21 (2.83, 3.63) 16 0.071
6-13 2.86 (2.63, 3.11) 28 0.125
Total 2.94 (2.85, 3.03) 224
Table 3.11. The mean nephelometric fibrinogen levels and the 13 haplotypes^or the peripheral vascular 
disease study. Values presented here are adjusted for age, sex and smoking. A  one way analysis o f 
variance (ANOVA) gave a p-value of 0.77. A  between group variablity o f 0% and a phenotypic 
variablity o f 3.4% were recorded.
Haplotype Mean Fibrinogen Level (95% Cl) Total Relative Frequency
1 4.22 (4.15, 4.29) 85 0.371
2 4.19 (4.09, 4.28) 54 0.236
3 4.12 (4.00, 4.24) 36 0.157
4 4.16 (3.97, 4.36) 10 0.044
5 4.19 (4.07, 4.32) 15 0.066
6 4.23 (4.08, 4.38) 12 0.052
7 4.18 (3.76, 4.61) 4 0.017
8 4.07 (3.78, 4.37) 6 0.026
9 3.72 1 0.0044
10 4.47 1 0.0044
11 4.39 1 0.0044
12 4.04 (2.17, 5.89) 2 0.0088
13 4.37 (3.91, 4.82) 2 0.0088
Total 4.19 (4.15, 4.23) 229
(jkrcK.
Table 3.12. The mean nephelometric fibrinogen levels and the 13 haplotypes^r the peripheral vascular 
disease study. Values presented here are unadjusted for age, sex and smoking. A  one way analysis o f 
variance (ANOVA) gave a p-value o f 0.22. A  between group variablity o f 1.2% and a phenotypic 
variablity o f 4.1% were recorded.
Haplotype Mean Fibrinogen Level (95% Cl) Total Relative Frequency
1 4.01 (3.83, 4.20) 80 0.354
2 4.19 (3.89, 4.49) 55 0.234
3 4.19 (3.89, 4.49) 37 0.164
4 4.39 (3.42, 5.37) 9 0.039
5 4.65 (4.13, 5.19) 16 0.011
6-13 4.28 (3.94, 4.62) 29 0.128
Total 4.18 (4.06, 4.31) 226
method of Sing and Davignon (1985) and as indicated varies from
2.4-4.9%.
155 individuals were genotyped with respect to the HaelII/beta 
polymorphism. There was no association between plasma fibrinogen level 
and any genotype (p=0.58) (Table 3.13). Differences in genotype
distribution between cases and controls was then analysed using . No 
significant difference in distribution was observed (p=0.55) (Table 
3.14). The contribution of genotype and smoking status to fibrinogen 
level was analysed. There was no relationship between the HaelII 
genotypes, smoking and fibrinogen level (Table 3.15).
3.4 Fibrinogen genotyping in peripheral vascular disease
The contribution of fibrinogen haplotype to the occurence of 
peripheral vascular disease was assessed by multiple logistic 
regression using dummy variables which represent the difference in the 
log odds of disease for each haplotype^relative to haplotype 1 (any 
haplotype could have been used as the reference group). The haplotype 
data was analysed to acertain whether haplotype was a factor 
associated with the presence of disease after accounting for a number 
of other possible risk factors. Eight models were used in the analysis 
and the data is presented in Tables 3.16-3.19. The first model was
adjusted for the variables packyears, height, non high density
lipoprotein (Non hdl), high density lipoprotein (HDL), triglyceride, 
current smokers (<5years), ex-smokers, age, sex, social class, and 
diabetic group (Table 3.16). Using this model haplotype 3 showed a 
significant association with disease (p<0.05) (Table 3.16). The second 
model was adjusted for smoking only (packyears, current smokers and 
ex-smokers). Using this model haplotypes 3 and 5 were found to have a
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Table 3.13. The mean level of fibrinogen recorded in the peripheral vascular disease study for the
Haelll polymorphism (adjusted for age, sex and smoking).
NO Individuals Genotype Mean Fibrinogen Level g/L 95% a
108 H lH l 2.92 (2.80 - 3.05)
42 H1H2 2.99 (2.76 - 3.24)
5 H2H2 2.68 (1.94 - 3.04)
p = 0.58 NS
NS = Not significant
Table 3.14 Comparison o f Genotype distribution between cases and controls for the H aelll 
polymorphism.
H lH l H1H2 H A
Control 61 20 2
Cases 52 24 3
= 1.18 p = 0.55
Table 3.15. Haelll genotypes w ith fibrinogen levels (measured by the clotting method) and smoking 
status.
Genotype
Never Smoked 
Mean (95% C.I) no.
Ever Smoked 
Mean (95% C.I) no.
Total
Mean (95% C.I) no
H lH l 2.85(2.65,3.07) 39 2.96(2.82,3.12) 69 2.92(2.81,3.05) 108
H1H2 2.77(2.44,3.15) 15 3.09(2.77,3.45) 24 2.99(2.76,3.24) 42
H2H2 2.79(0.15,52.3) 2 2.60(1.29,5.21) 3 2.68(1.94,3.69) 5
p-value 0.91 0.42 0.58
Table 3.16. logistic regression for haplotypes 2-8 relative to genotype 1 with the log odds of disease
adjusted for variables listed below. The odds ratio (OR) gives the relative increase in odds of disease
of the genotype in question when compared with haplotype 1.
Haplotypes Odds Ratio (95% Cl) Odds Ratio (95% O )
Adjusted for Adjusted for
Fibrinogen, smoking, lipids etc age, sex &  smoking
Haplotype 2: Haplotype 1 0.96 (0.32, 2.88) 0.95 (0.40, 2.27)
Haplotype 3: Haplotype 1 6:31 (1.55, 25.64)* 4.56 (1.55, 13.39)*
Haplotype 4: Haplotype 1 6.14 (0.37, 43.44)+ 2.99 (0.67, 13.32)
Haplotype 5: Haplotype 1 6.87 (0.99, 47.23)+ 9.17 (1.84, 45.72)*
Haplotype 6; Haplotype 1 0.13 (0.02, 1.02)+ 0.41 (0.08, 1.99)
Haplotype 7; Haplotype 1 8.25 (0.17, 399.8) 3,39 (0.20, 56.41)
Haplotype 8: Haplotype 1 0.17 (0.01, 2.14) 0.24 (0.03, 1.96)
Included variables:
(Fibc) p=0.019
Packyears p<0.001 p<0.001
Height p=0.014 -
Nonhdl p=0.001 -
Hdl p=0.25 -
(Triglyceride) p=0.74 -
Current Smoker p=0.77 p=0.47
Ex-smoker p=0.77 p=0.47
Age p=0.18 p=0.32
Sex p=0.18 p=0.04
Social class p=0.77 -
Diabetic group p=0.56 -
+
*
*$
* * *
p<0.1
p<0.05
p<0.01
p<0.001
Table 3.17 logistic regression for haplotyes 2-8 relative to haplotype 1 with the log odds of disease
adjusted for variables listed. The odds ratio (OR) gives the relative increase in odds of disease of the
haplotype in question when compared with haplotype 1.
Haplotypes Odds ratio (95% Cl) 
Adjusted for plasminogen 
activator/inhibitor, 
age, sex & smoking
Odds ratio (95% Cl) 
Adjusted for lip id 
peroxide, age, 
sex & smoking
Haplotype 2: Haplotype 1 1.09 (0.45, 2.64) 1.00 (0.42, 2.41)
Haplotype 3: Haplotype 1 4.53 (1.44, 14.27)* 4.29 (1.41, 13.06)*
Haplotype 4: Haplotype 1 3.55 (0.80, 15.66) 2.42 (0.53, 11.05)
Haplotype 5: Haplotype 1 9.14 (1.77, 46.60)* 9.61 (1.89, 48.75)*
Haplotype 6: Haplotype 1 0.43 (0.08, 2.20) 0.45 (0.09, 2.16)
Haplotype 7: Haplotype 1 2.42 (0.11, 53.25) 3.42 (0.15, 80.27)
Haplotype 8: Haplotype 1 0.29 (0.03, 2.58) 0.22 (0.03, 1.92)
Included variables:
Plasminogen
Activator inhibitor p=0.02 -
Packyears p<0.001 p<0.001
Current Smoker p=0.55 p=0.59
Ex-smoker (<5 years) p=0.58 p=0.67
Age p=0.26 p=0.33
Sex p=0.08 p=0.05
Lipid peroxide
’
p=0.15
+
*
**
$ * *
p<0.1
p<0.05
p<0.01
p<0.001
Table 3.18. logistic regression for haplotypes 2-8 relative to haplotype 1 with the log odds of disease
adjusted for the variables listed below. The odds ratio (OR) gives the relative increase in odds of
disease of the haplotype in question when compared with haplotype 1.
Haplotype Odds ratio (95% Cl) 
Adjusted for 
Nephelometic Fibrinogen, 
age, sex &  smoking
Odds ratio (95% Q ) 
Adjusted 
Von Willebrand factor 
age, sex &  smoking
Haplotype 2: Haplotype 1 0.95 (0.38, 2.36) 1.02 (0.42, 2.46)
Haplotype 3: Haplotype 1 4.05 (1.32, 12.44)* 4.43 (1.53, 12.92)**
Haplotype 4: Haplotype 1 2.75 (0.62, 12.23) 2.53 (0.55, 11.54)
Haplotype 5: Haplotype 1 7.59 (1.44, 40.11)* 10.22 (1.99, 52.47)**
Haplotype 6: Haplotype 1 0.28 (0.05, 1.56) 0.37 (0.07, 1.94)
Haplotype 7: Haplotype 1 3.20 (0.17, 60.05) 4.03 (0.19, 83.82)
Haplotype 8: Haplotype 1 0.22 (0.3, 1.84) 0.23 (0.03, 1.94)
Included variables:
Nephelometic Fibrinogen p=0.10
Packyears p<0.001 p<0.001
Current smoker p=0.06 p=0.48
Ex smoker (<5 years) p=0.59 p=0.88
Age p=0.34 p=0.19
Sex p=0.04 p=0.05
Von Willebrand factor p=0.06
+ p<0.1
* p<0.05
** p<0.01
p<0.001
Table 3.19. logistic regression for haplotypes 2-8 relative to haplotype 1 with the log odds of disease
adjusted for the variables listed below. The odds ratio (OR) gives the relative increase in odds of
disease of the haplotype in question when compared with haplotype 1.
Haplotypes Odds ratio (95% Cl) Odds ratio (95% Cl)
Adjusted for Adjusted for crosslinked fibrin
P thromboglobulin, degredation products.
age & smoking age &  smoking
Haplotype 2: Haplotype 1 1.33 (0.52, 3.38) 0.98 (0.40, 2.40)
Haplotype 3: Haplotype 1 2.84 (0.87, 9.25) 3.75 (1.23, 11.45)*
Haplotype 4: Haplotype 1 2.75 (0.58, 13.01) 2.80 (0.59, 13.37)
Haplotype 5: Haplotype 1 6.59 (1.22, 35.62)* 7.58 (1.43, 40.16)*
Haplotype 6: Haplotype 1 0.44 (0.09, 2.21) 0.35 (0.07, 1.85)
Haplotype 7: Haplotype 1 2.47 (0.11, 54.23) 2.97 (0.18, 49.29)
Haplotype 8: Haplotype 1 0.23 (0.03, 2.06) 0.28 (0.03, 2.41)
Included variables:
6 Thromboglobulin p=0.04
Packyears p<0.001 p<0.0001
Current Smoker p=0.81 p=0.80
Ex-smoker p=0.50 p=0.47
Age
Cross-linked fibrin
p=0.39 p=0.12
degredation products p=0.02
**
* * *
p<0.1
p<0.05
p<0.01
p<0.001
Table 3.20 Comparison of allele frequencies between cases and controls for 
the Tag I (A,a), Bell (B,k) KpnI/SacI (D,d) and Hae III (H1,H2) polymorphic 
loci
Allele frequencies 
Cases Controls
0.761
0.239
0.776
0.224
chi-square = 0.146 
(NS)
0.803
0.197
0.903
0.097
chi-square = 9.48 
(P<0.005)
0.778
0 . 2 2 2
0.758
0.242
chi-square = 0.262 
(NS)
HI
H2
0.810
0.190
0.855
0.145
chi-square = 1.196 
(NS)
significant association with disease (p=0.05) (Table 3.16). The 
remaining six models were adjusted for age, sex and smoking and one of 
the following: clottable fibrinogen (Table 3.16), plasminogen
activator inhibitor (Table 3.17), lipid peroxide (Table 3.17), 
nephelometric fibrinogen (Table 3.18), Von Willebrand factor (Table 
3.18) and cross-linked fibrin degredation products (Table 3.19). In 
these six models haplotypes 3 and 5 were again found to have a 
significant association (p<0.05) with disease over and above the level 
of fibrinogen and other risk factors. The log odds ratio of disease 
for haplotypes 2-13 relative to haplotype 1 are presented in Tables 
3.16-3.19. From Tables 3.16-3.19 the log odds ratio of disease for
haplotypes 3 and 5 are significantly higher than that of the reference
, , .  ^ Table 3.20 compares allele frequencies in cases andhaplotype 1.
controls and shows a highly significant (p<.0.005) difference for the
Bell polymorphism
3.5 Fibrinogen genotyping in the Ladywell study
168 genomic DNA samples were analysed in the hypertension
study using the restriction enzyme Bell and the beta fibrinogen cDNA 
probe. Gene frequencies were calculated by gene counting and are
presented in Appendix 4. The Bell/beta cDNA fibrinogen polymorphism 
allele frequencies were 0.85 (for B the 5.3Kb fragment) and 0.15 (for 
b the 0.15Kb fragment). The overall genotype frequencies were compared 
with those predicted from the Hardy-Weinberg equilibrium and no 
significant differences were noted (Table 3.21). A comparison of the 
Bell genotype distribution was carried out between the four different 
groups in the Ladywell study (Table 3.2R). No statistically
significant differences were recorded in the genotype distribution 
between the four groups.
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Table 3.21 A  comparison o f observed and expected numbers o f persons in the Ladywell hypertension 
study o f different Bcll/beta fibrinogen cDNA RFLP assuming Hardy-Weinberg equilibrium.
Genotype Bell
Polymorphism
X"
BB 117 118.5
Bb 47 45.0 0.13 (NS)
bb 4 4.3
Table 3.2Z Comparison o f Bcll/beta fibrinogen cDNA RFLP distribution between the four groups in 
the Ladywell hypertension Study. Group A  is low parental/high offspring blood pressure, group B is 
high parental/high offspring blood pressure; group C is low parental/low offspring blood pressure and 
group D is high parental/low offspring blood pressure.
Genotype Group A Group B Group C Group D
Obs. No.
BB 31 31 27 28
Bb 8 11 13 15
bb 2 1 1 0
Exp. No.
BB 29.6 31.1 27.6 29.6
Bb 10.5 11 12.1 12.1
bb 0.9 1 1.3 12
X" 0.74 0.0003 0.05 0.925
E x ' 1.75
4.0 DISCUSSION
4.1 Fibrinogen genotype frequencies
A comparison of RFLP frequencies, at the alpha, beta and gamma 
fibrinogen loci, observed in this study with those reported in 
previous studies is presented in Table 4.1. From Table 4.1 it can be 
seen that the observed frequencies are broadly similar. The Bell 
polymorphism frequency recorded in this study did not show a
statistically significant difference from that reported by Berg and 
Kierulf (1989) (X2=1.28, p=>0.80) but was statistically different from 
that of Humphries et al. (1987) (X^ =7.28, p=<0.05). It was not
possible to carry out a similar comparison between these results and 
those reported in an American study (Murray et al. 1987) for the 
KpnI/SacI polymorphism associated with the gamma fibrinogen gene as 
the number of individuals of each genotype was not reported. Observed 
differences might be chance or might represent a true population 
difference which further studies should clarify.
4.2 Linkage Disequilibrium
Linkage disequilibrium was predicted based on the calculation 
of the probability of association between the Taql/alpha and
Bcll/beta, the Taql/alpha and KpnI/SacI/gamma, the Bcll/beta and 
Kpnl/Sad/gamma and the Bcll/beta and HaelII/beta DNA markers (Table 
3.3.). Association was found between all four combinations with the 
highest degree of association between the Taql/alpha and
Kpnl/SacI/gamma markers and the Bcll/beta and HaelII/beta markers. The 
degrees of association seen here would be as expected according to 
physical mapping data for the three fibrinogen genes and suggest 
strong linkage disequilibrium between the alpha and gamma loci and
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Table 4.1. Reported Fibrinogen gene frequencies for the Scottish, English, Norwegian and American 
populations.
Enzyme/
probe
Polymorph. PVD PVD 
bands (Kb) 1991 1991
Scottish Scottish
Ladywell Humphries Berg Murray Thomas 
1991 1987 1989 1987 1991 
Scottish English Norwegian American English
Taql/pAF 12.4 (A) 0.75 0.63 0.73
1.6 (a) 0.25 0.33 0.23
BclI/pFB5 5.3 (B) 0.85 0.84 0.75 0.83
4.2 (b) 0.15 0,16 0.25 0.17
KpnI/SacI/ 11 (D) 0.76 0.82
FFGI 14(d) 0.24 0.18
Haelll 0.575 (H I) 0.81 0.82
0.383
0.958 (H2) 0.19 0.18
No. individuals 
Analysed 235 170 168 91 55/118 
a  fi
~50 292
beta/BclI and beta/Haelll markers with much weaker linkage 
disequilibrium between the alpha and beta and the beta and gamma loci* 
A lack of association between any of the four markers would be 
unexpected as all three genes are relatively close to each other. The 
high degree of association between the Taql/alpha and the 
Kpnl/SacI/gamma markers and the Bcll/beta and Haelll/beta markers 
would suggest that the physical distance between these markers is 
small resulting in a low rate of recombination in the interval and 
that the beta locus is either further away from the alpha and gamma 
loci or has a higher frequency of recombination in the interval 
(Figure 4.1). These results are consistant with those of other authors 
(Table 4.2). Physical mapping of the three genes gives a relative 
order of Ialpha,fgamma^ beta with similar distance between each. Hence 
relative weaker association of beta to alpha/gamma is not due to 
distance but may represent a relative hotspot for recombination which 
arose during the evolution of the three genes. It is believed that the 
ancestral genes duplicated giving rise to the alpha gene and 
pre-beta/gamma genes. Further duplication of the pre-beta/gamma genes 
resulted in individual beta and gamma genes. The present arrangement 
of the three fibrinogen genes may be explained in one of two ways. The 
first theory involves a three step mechanism where duplication of the 
ancestral gene and then of the pre-beta gamma genes is followed by 
inversion of the alpha/gamma region. The second theory is a two step 
mechanism in which duplication of the ancestral gene is followed by 
remote transposition and inversion (Kant et al., 1985). By either 
mechanism there must be at least one recombination in the 
alpha/gamma-beta interval.
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Figure 4.1. Organisation of the three fibrinogen genes according to physical mapping data and the 
linkage disequilibruim data o f the four gene markers the TaqI, Bell, KpnI/SacI and Haelll variable sites. 
The bold lines indicate strong association, all other lines indicate an association but to a lesser degree.
Table 4.2. The Standardised disequilibrium coefficient (A) and p-values for the a-Taql/p-BclI, P-Bcll/
Y-KpnI/SacI a-Taql/Y-KpnI/SacI and P-BclI/p-Haelll loci as reported in this study and that of
Aschbacher and Murray.
No. of chromosomes 
studied
A Value p-value
a-Taql/p-B clI
Aschbacher(1985) - 0.01 0.59
Murray (1985) -100 0.071 0.327
Present study (1991) 466 0.142 6.6 X 10"
P-BcH/y-Kpnl/SacI
Aschbacher (1985) - 0.10 0.33
Murray (1985) -100 0.129 0.109
Present study (1991) 466 0.145 2.5 X 10 '
a-Taql/y-Kpnl/SacI
Aschbacher(1985) - -0.88 <0.001
Murray (1985) -100 -0.884 <0.0001
Present study (1991) 470 0.698 1.1 X 1 0 "
P-Bcll/P H a e lll
Present Study 1991 340 0.462 2.2 X 10 ®
Association between the three loci was calculated based on a 
method by Chakravati using Fishers exact probability. Here the 
relationship between the delta value and the p-value depends upon the 
sample size (ie the larger the sample the smaller the p-value) and the 
more likely association between the points of interest. Thus when 
comparing the probability of association calculated for samples of 
greatly differing size it is important to take into account the effect 
of sample size on the resulting p-value. From table 4.2 the p-value 
decreases in proportion to the sample size thus using this method it 
is not possible to calculate the strength of linkage disequilibrium 
but only to predict the strength based on the degree of association 
observed and the size of sample used.
Although no association has been found between the Taql/alpha 
and Bcll/beta and the Bcll/beta and Kpnl/Sad/gamma markers by other 
authors it cannot be excluded given the size of these studies. An 
extremely large sample size would be necessary for the demonstration 
of negative linkage disequilibrium (Thompson et al. 1988). Based on 
this argument the apparent linkage equilibrium reported by Murray et 
al. (1985), calculated using data obtained from the analysis of 100 
chromosomes, would need further investigation.
4.3 Relationship of fibrinogen level to genotype
Multiple statistical analyses of data recorded in this study 
failed to demonstrate any significant correlation of fibrinogen 
genotype with fibrinogen levels (Tables 3.4-3.7 and 3.9-3.13.) Three 
other studies have addressed this question. Humphries et al. (1987) 
carried out an RFLP analysis on 66 healthy men and 25 healthy women 
with a mean age of 46 years and of whom 15% were cigarette smokers.
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Fibrinogen levels were adjusted for age, sex and smoking habits. The 
results showed that individuals homozygous for the less common Bell 
site at the beta fibrinogen locus had the highest mean fibrinogen 
level (3.69g/l) whereas individuals who were homozygous for the common 
allele had a value of 2.74g/l with heterozygotes having an 
intermediate value of 2.98g/l. A one way fmalysis of variance showed 
that these differences were statistically significant. Differences in 
fibrinogen level associated with the TaqI polymorphism at the alpha 
fibrinogen locus were not statistically significant. A comparison of 
fibrinogen level and genotype for the TaqI and Bell polymorphisms 
reported by Humphries et al. (1987) and Berg and Kierulf. (1989) and 
those recorded in this study is presented in Table 4.3. Humphries et 
al. (1987) report that the overall genetic variation associated with 
the TaqI and Bell polymorphisms contributes 13.2% of the total
phenotypic variance in fibrinogen levels. In this and Berg and
Kierulfs (1987) study a much lower contribution to phenotypic 
variance, 2.4-4.9%, was apparent (Tables 3.9-3.12).
The results of Humphries et al. (1987) were not confirmed by a 
Norwegian study. Berg and Kierulf (1989) studied 178 healthy unrelated 
individuals recruited from monozygotic twins and their families. The 
twins were aged between 38 and 57 years with a mean age of 44 years. 
One twin was chosen at random from each pair forming a group of
unrelated people for use in association analysis. Of the 178
individuals recruited 118 were studied for the Bell polymorphism at 
the beta gene and 60 were studied for the TaqI polymorphism at the 
alpha gene. Quantitative fibrinogen levels were measured by the 
standard thrombin clotting time technique (Clauss, 1957) in each pair 
of twins for heritability analysis. Fibrinogen levels were adjusted
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Table 4.3. The mean fibrinogen levels (adjusted for age, sex and smoking habit) and p-values for the 
TaqI and Bell polymorphisms in the present peripheral vascular disease study and those reported by 
Humphries et al. (1987) (on healthy subjects) and Berg and K ierulf (1989) (adjusted for age, and sex 
only using healthy subjects).
Genotype Humphries 
No. individuals
Mean Present study 
fibrinogen No. individuals 
(g/L)
Mean Berg &  K ieru lf 
fibrinogen No. individuals 
(g/L)
Mean
fibrinogen
(g/L)
AA 47 3.00 133 2.94 35 2.90
Aa 37 2.74 87 2.94 18 2.91
aa 7 2.76 15 2.90 7 3.00
p-value <0.2 <0.83 p>0.05
BB 50 2.74 168 2.94 79 2.79
Bb 37 2.98 59 2.91 37 3.00
bb 4 3.69 6 2.99 2 2.95
p-value <0.025 <0.67 p>0.05
for age and sex. Gene frequencies and mean fibrinogen concentrations 
reported by Berg and Kierulf (1989) are similar to those reported by 
Humphries et al. (1987), however, no association was found between 
plasma fibrinogen concentrations and any genotype for either of the 
two fibrinogen polymorphisms examined (Table 4.3). Furthermore the 
heritability of fibrinogen levels, calculated using the intraclass 
correlation coefficient in monozygotic twin pairs, indicated a lower 
level of heritability (0.29) than that (0.51) estimated by Hamsten et 
al. (1987).
The number of individuals involved in this study was larger 
(235) than that (91) studied by Humphries et al. (1987). Humphries et 
al. (1987) reported a significant increase in fibrinogen level with 
genotype however the relative frequency of homozygotes for the rare 
allele for the Bell polymorphism was low (4 individuals) and 
calculation of fibrinogen concentration was based on a single 
measurement. In this study the sample population was Scottish and 
divided into patients and controls whereas the sample population 
studied by Humphries et al. (1987) was healthy and of English origin.
More recently Thomas et al. (1991) used a new polymorphism at 
the beta fibrinogen locus, detected by the enzyme Haelll, to analyse a 
group of 292 healthy men aged 45-69 years. The group was divided into 
120 smokers and 172 non-smokers. A significant association was found 
between fibrinogen levels and genotype in both and accounted for 3.1% 
of the variance in fibrinogen levels. The present study failed to show 
any association between the Haelll polymorphism, smoking and 
fibrinogen level (Table 3.15). However, the population used here was a 
mixture of men and women, 50% of the sample had peripheral arterial
Page 43
disease and the number of individuals of the genotype H2H2, the 
genotype Thomas et al. (1991) had previously associated with an 
increase in fibrinogen levels, was too low for any significant
comparison to be made. Table 4.4 compares the results from this study 
and those reported by Thomas et al. (1991).
155 individuals in the PVD case and control study were
genotyped with respect to the Haelll polymorphism at the beta 
fibrinogen locus no statistically significant difference in mean 
fibrinogen level was recorded between the three groups (Table 3.13). 
The difference in genotype distribution between cases and controls was 
analysed using and no significant difference was recorded (p=0.55) 
(Table 3.14)
From this study there is no evidence of a statistically
significant correlation between fibrinogen level and genotype for thé
polymorphisms studied. These findings differ from those of Humphries 
et al. (1987) and Thomas et al. (1991) but are in agreement with those 
of Berg and Kierulf (1989). However further studies are required.
4.4 Fibrinogen Genotyping in the Ladywell Study
The fibrinogen genotype analysis carried out on the Ladywell 
subjects detected no significant variation in the allelic frequencies 
of the four groups studied with the Bell polymorphism. This approach 
needs to be supported by sib pair analysis before concluding that the 
fibrinogen beta gene does not have a role in the determination of 
blood pressure.
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Table 4.4 Comparison o f H aelll genotype, Mean fibrinogen level (measured by the clotting method) 
and smoking status reported in this study and that o f Thomas et al. (1991).
Thomas et al 
1991
Mean (SD) 
Fib. (g/L)
Present
Study
Mean (95% Cl) 
Fib. (g/L)
Non Smokers No. Individuals
H lH l 115 2.58 (0.51) 39 2.85 (2.65, 3.07)
H1H2 49 2.81 (0.64) 15 2.77 (2.44, 3.15)
H2H2 8 2.91 (0.62) 2 2.79 (0.15, 52.3)
p-value 0.42
Smokers
H lH l 75 2.90 (0.64) 69 2.96 (2.82, 3.12)
H1H2 42 3.18 (0.87) 24 3.09 (2.77, 3.45)
H2H2 3 3.32 (0.58) 3 2.60 (1.29, 5.21)
p-value 0.91
A ll
H lH l 190 2.71 (0.59)* 108 2.92 (2.81, 3.05)
H1H2 91 2.98 (0.77) 42 2.99 (2.76, 3.24)
H2H2 11 3.02 (0.61) 5 2.68 (1.94, 3.69)
p-value 0.58
* Analysis o f Variance: F=5.64, P<0.004
4.6 Fibrinogen Genotyping and Peripheral Vaiscular Disease
A comparison of haplotype distribution between cases and 
controls was carried out using . The overall X^  was not 
statistically significant. However, when individual haplotype 
distributions were considered haplotypes 3, 4, 5 and 7 were more
predominant in the cases than controls, with the difference in 
distribution of haplotype 5 reaching statistical significance (p<0.05) 
(Table 3.8). It should be noted, however, that the probability of 
recording a significant result due to chance alone increases with the 
number of statistical tests applied.
The haplotype data was analysed by multiple logistic 
regression to acertain whether haplotype was associated with the 
presence of disease after accounting for a number of other possible 
risk factors (Tables 3.16-3.19). Haplotype 1 was used as the reference 
group for the analyses and the odds ratios of disease for haplotypes 
2-13 relative to haplotype 1 are presented in Tables 3.16-3.19. 
Several models were used in the analysis. When the model included the 
variables packyears, height, non high density lipoprotein (Non hdl), 
high density lipoprotein (HDL), triglyceride, current smokers 
(<5years), ex-smokers, age, sex, social class, and diabetic group, 
haplotype 3 was found to be a significant predictor of disease 
(p<0.05). The second model was adjusted for age, sex and smoking 
(packyears, current smokers and ex-smokers). Using this model 
haplotypes 3 and 5 were found to be significant predictors of disease 
(p=0.05). The remaining six models were adjusted for age, sex, smoking 
and one of the following: plasminogen activator inhibitor, lipid
peroxide, clottable fibrinogen, nephelometric fibrinogen. Von 
Willebrand factor and cross-linked fibrin degradation products. In
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these six models haplotypes 3 and 5 were found to be significant 
predictors of disease over and above the level of fibrinogen and other 
risk factors. From the odds ratios haplotypes 3 and 5 are more 
susceptible to peripheral arterial disease than the other haplotypes 
irrespective of fibrinogen level. Thus individuals with these 
haplotypes may be genetically predisposed to peripheral vascular 
disease. This suggests that it may not be the level of fibrinogen but 
the molecular structure that is important. A genetic variant of 
fibrinogen has been reported in a 30 year old female presenting with 
arterial occlusion of the lower limbs (Brook et al., 1983). The woman 
was found to have an abnormal thrombin and reptilase time. Further 
investigation revealed an abnormal fibrinogen which has now been 
named fibrinogen 'Haifa*. The abnormality was localised to the carboxy 
terminal of the gamma chain resulting in abnormal fibrin monomer 
polymerization. The abnormal fibrinogen was found to be heritable with 
an identical abnormality being found in the probands mother and son 
(Brook et al., 1983).
In this study a statistically significant association was 
detected between fibrinogen haplotype and the occurence of peripheral 
vascular disease. There are no comparable studies on peripheral 
vascular disease in the medical literature and in view of the clinical 
importance of these ob servations other studies of this nature, in 
peripheral vascular disease and other cardiovascular diseases, are 
indicated. More haplotype studies would be necessary to confirm the 
results of this study and to acertain exactly which are ’high risk* 
haplotypes and to what degree individuals of a particular haplotype 
are at risk. Family studies would also have to be performed to clarify 
the phase at each fibrinogen locus within the combined haplotype.
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The next step would then be to sequence the fibrinogen 
genes associated with the particular haplotype, to identify mutations 
and determine which ones are pathogenic with the eventual aim of 
predicting cardiovacular disease. An understanding of the disease 
mechanism at the molecular level will aid in counselling those known 
to be predisposed to CVD. The ability to characterise RFLPs and prove 
association with disease would also allow screening of individuals 
thought to be at risk. If a genetic predisposition to CVD can be 
proved, screening and genetic counselling are feasible propositions 
with the ultimate aim of targetted disease prevention.
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APPENDIX 1
MATERIALS and SOLUTIONS
DNA Extraction
Lysis buffer:
Nuclei lysis buffer:
Proteinase K: 
10% SDS:
NaCl:
Phenol/Chloroform mix;
TE buffer:
Loading mix:
0.32M Sucrose
lOmM Tris/HCl pH 7.5
5mM MgC12
1% Triton X-100
10mm Tris
0.44M NaCl
2mM EDTA pH 8.2
lOmg/ml
SDS lOOg
H20 900ml
adjusted pH to 7.2 with cone HCl^  /Lia
ujo.f'C' aclcltcl fo 10 0 0 ^
6M
1:1 ratio of water saturated 
phenol (equilibrated with tris to 
pH 7.5; 0.1% 8-hydroxy-quinoline) 
and chloroform 
lOmM Tris(pH7.5)
ImM EDTA(PHS.O)
50% Glycerol 
2% Ficoll 
50Mm EDTA
1Kb Ladder marker: 25 ul DNA Ladder
725 ul H2O
100 ul Loading mix
Southern Blotting 
50 X EB:
Electrophoresis buffer:
Depurination solution: 
Dénaturation solution:
Neutralisation solution:
20x SSC:
Tris base 242g/l
Glacial acetic acid 57,lml/l
0.5M EDTA (pH 8.0) 100ml
0.04M Tris
0.0002M EDTA
0.25M HCl
0.5M NaOH
1.5M NaCl
3.0M NaCl
0.5M Tris HCl(pH7.4)
3.0M NaCl
300mM Sodium citrate
Prehybridisation/Hybridisation 
Cambridge prehyb:
100 X Denhardts solution:
Ethidium bromide solution: 
Sephadex G-50:
Stripping solution:
2x Denhardts solution 
4.5x SSC 
0.1% SDS 
6% w/v PEG 
2% Ficoll
2% Bovine serum albumin 
2% Polyvinylpyrolidone 
lOug/ml in H2O
30g sephadex/500ml lxSSC/0.1%SDS 
0.4M NaOH
Plasmid preparation 
L.Broth-per litre:
Tetracycline:
Lysis solution:
Sodium hydroxide/
Sodium dodecyl sulphate: 
Tris/HCl:
Sodium Acetate:
Isopropanol:
70% Ethanol: 
Chloroamphenicol: 
Ethidium bromide:
lOg bacto-tryptone 
5g yeast extract 
lOg NaCl 
0.0125g/ml
(O.Olmg/ml tetracycline)
50mM glucose 
25mM Tris 
lOmM EDTA pH 8 
Lysosyme 2mg/ml
0.2M NaOH/1% SDS
0.05M Tris adjust to pH 8 with cone 
HCl
3M NaAc adjust to pH 4.8 with 
glacial acetic acid
34mg/ml ethanol 
5mg/ml
PCR
0.5X TBE Buffer:
lOX Reaction Buffer:
90mM Tris base 
90mM Boric acid 
ImM EDTA
lOOmM Tris-HCl pH 8.3 at 25°C 
500mM KCl 
15mM MgC12 
0.1% gelatin
dNTPs (Stock lOuM): Dilute to 2 uM
Take 50ul of dATP 
dCTP 
dTTP 
dGTP
and 50ul SDW
Total Vol = 250ul of 2uM dNTP mix
Use lOul per reaction 
Gives final concentration of 200uM 
dNTP per reaction 
PCR Reaction Mixture: 5 ul dNTPs 2 uM
5 ul lOx buffer 
1 ul 766L primer 
1 ul 767L primer 
1 ug DNA
O.Sul Taq Polymerase 
SDW (volume as required)
Total volume = 50ul 
A 1ml master mix may be prepared based on the above volumes and the 
required reaction volume removed as needed.
PCR Programmes
1 Cycle:-
Dénaturation:
Annealing:
93°C for 3 min 
55°C for 1 min 
72°C for 2 min
30 Cycles:-
Dénaturation: 93°C 1 min
Annealing: 55°C 1 min
Extension: 72°C 2 min
Haelll Digests 
8 units (3ul) Haelll 
4ul react 2 
43 ul PCR product 
Total volume=50ul
APPENDIX 2
Fibrinogen genotype results in the peripheral vascular disease 
case-control study for the TaqI, Bell and KpnI/SacI polymorphism.
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0003X R0329-89 TaqI pAFl 2.4/0.7 AA
R0329-89 Bell pFB5 6.6/5.3/4.2 Bb
R0329-89 KpnI/SacI pFGl 11 DD
0004K R0326-89 TaqI pAFl 1,6/0.7 aa
R0326-89 Bell pFB5 6.6/5.3 BB
R0326-89 KpnI/SacI pFGl 14 dd
0005W R0523-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0523-89 Bell pFB5 6.6/5.3 BB
R0523-89 KpnI/SacI pFGl 14/11 Dd
0006H R0322-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0322-89 Bell pFB5 6.6/5.3 BB
R0322-89 KpnI/SacI pFGl 11 DD
0007V R0328-89 TaqI pAFl 2.4/0.7 AA
R0328-89 Bell pFB5 6.6/5.3/4.2 Bb
R0328-89 KpnI/SacI pFGl 11 DD
0008E R0327-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0327-89 Bell pFB5 6.6/5.3 BB
R0327-89 KpnI/SacI pFGl 14/11 Dd
0009R R0325-89 TaqI pAFl 2.4/0.7 AA
R0325-89 Bell pFB5 6.6/5.3/4.2 Bb
R0325-89 KpnI/SacI pFGl 11 DD
OOlOX R0324-89 TaqI pAFl 2.4/0.7 AA
R0324-89 Bell pFB5 6.6/5.3/4.2 Bb
R0324-89 KpnI/SacI pFGl 11 DD
OOllK R0612-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0612-89 Bell pFB5 6.6/5.3 BB
R0612-89 KpnI/SacI pFGl 14/11 Dd
0012W R0614-89 TaqI pAFl 2.4/0.7 AA
R0614-89 Bell pFB5 6.6/5.3/4.2 Bb
R0614-89 KpnI/SacI pFGl 11 DD
0013H R0617-89 TaqI pAFl 2,4/1.6/0.7 Aa
R0617-89 Bell pFB5 6.6/5.3 BB
R0617-89 KpnI/SacI pFGl 14/11 Dd
0014V R0616-89 TaqI pAFl 2.4/0.7 AA
R0616-89 Bell pFB5 6.6/5.3 BB
R0616-89 KpnI/SacI pFGl 11 DD
0015E R0599-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0599-89 Bell pFB5 6.6/5.3 BB
R0599-89 KpnI/SacI pFGl 14/11 Dd
0016R R0615-89 TaqI pAFl 2.4/0.7 AA
R0615-89 Bell pFB5 6.6/5.3 BB
R0615-89 KpnI/SacI pFGl 11 DD
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0017B R0597-89 TaqI pAFl 2.4/0.7 AA
R0597-89 Bell pFB5 6.6/5.3/4.2 Bb
R0597-89 KpnI/SacI pFGl 11 DD
0020H R0587-89 Taql pAFl 2.4/0.7 AA
R0587-89 Bell pFB5 6.6/5.3 BB
R0587-89 KpnI/SacI pFGl 11 DD
0021V R0613-89 Taql pAFl 2.4/0.7 AA
R0613-89 Bell pFB5 6.6/5.3/4.2 Bb
R0613-89 KpnI/SacI pFGl 11 DD
0022E R0594-89 Taql pAFl 2.4/0.7 AA
R0594-89 Bell pFB5 6.6/5.3 BB
R0594-89 KpnI/SacI pFGl 11 DD
0023R R0600-89 Taql pAFl 2.4/1.6/0.7 Aa
R0600-89 Bell pFB5 6.6/5.3/4.2 Bb
R0600-89 KpnI/SacI pFGl 14/11 Dd
0024B R0598-89 Taql pAFl 2.4/1.6/0.7 Aa
R0598-89 Bell pFB5 6.6/5.3 BB
R0598-89 KpnI/SacI pFGl 14/11 Dd
0025M R0589-89 Taql pAFl 2.4/0.7 AA
R0589-89 Bell pFB5 6.6/5.3 BB
R0589-89 KpnI/SacI pFGl 11 DD
0026A R0593-89 Taql pAFl 2.4/1.6/0.7 Aa
R0593-89 Bell pFB5 6.6/5.3/4.2 Bb
R0593-89 KpnI/SacI pFGl 14/11 Dd
0027L R0596-89 Taql pAFl 2.4/1.6/0.7 Aa
R0596-89 Bell pFB5 6.6/5.3 BB
R059G-89 KpnI/SacI pFGl 14/11 Dd
0028X R0604-89 Taql pAFl 2.4/0.7 AA
R0604-89 Bell pFB5 6.6/5.3 BB
R0604-89 KpnI/SacI pFGl 11 DD
0029K R0610-89 Taql pAFl 2.4/1.6/0.7 Aa
R0610-89 Bell pFB5 6.6/5.3 BB
R0610-89 KpnI/SacI pFGl 14/11 Dd
0030V R0793-89 Taql pAFl 2.4/0.7 AA
R0793-89 Bell pFB5 6.6/4.2 bb
R0793-89 KpnI/SacI pFGl 11 DD
0032M R0583-89 Taql pAFl 2.4/0.7 AA
R0583-89 Bell pFB5 6.6/5.3 BB
R0583-89 Kpnl/SacI pFGl 11 DD
0033A R0601-89 Taql pAFl 2.4/0.7 AA
R0601-89 Bell pFB5 6.6/5.3 BB
R0601-89 KpnI/SacI pFGl 11 DD
0034L R0621-89 Taql pAFl 2.4/0.7 AA
R0621-89 Bell pFB5 6.6/5.3/4.2 Bb
R0621-89 KpnI/SacI pFGl 11 DD
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0035X R0581-89 Taql pAFl 2.4/1.6/0.7 Aa
R0581-89 Bell pFB5 6.6/5.3 BB
R0581-89 KpnI/SacI pFGl 11 DD
0036K R0590-89 Taql pAFl 1.6/0.7 aa
R0590-89 Bell pFB5 6.6/5.3 BB
R0590-89 KpnI/SacI pFGl 14 dd
0037W R0588-89 Taql pAFl 2.4/1.6/0.7 Aa
R0588-89 Bell pFB5 6.6/5.3 BB
R0588-89 KpnI/SacI pFGl 14/11 Dd
0038H R0609-89 Taql pAFl 2.4/0.7 AA
R0609-89 Bell pFB5 6.6/5.3 BB
R0609-89 KpnI/SacI pFGl 11 DD
0039V R0586-89 Taql pAFl 2.4/0.7 AA
R0586-89 Bell pFB5 6.6/5.3/4.2 Bb
R0586-89 KpnI/SacI pFGl 11 DD
0040A R0607-89 Taql pAFl 2.4/0.7 AA
R0607-89 Bell pFB5 6.6/5.3 BB
R0607-89 KpnI/SacI pFGl 11 DD
0041K R0591-89 Taql pAFl 2.4/0.7 Aa
R0591-89 Bell pFB5 6.6/5.3/4.2 Bb
R0591-89 KpnI/Sael pFGl 11 DD
0042X R0592-89 Taql pAFl 2.4/0.7 AA
R0592-89 Bell pFB5 6.6/5.3/4.2 Bb
R0592-89 KpnI/Sael pFGl 11 DD
0043K R0606-89 Taql pAFl 2.4/0.7 AA
R0606-89 Bell pFB5 6.6/5.3 BB
R0606-89 KpnI/SacI pFGl 11 DD
0044W R0603-89 Taql pAFl 2.4/0.7 AA
R0603-89 Bell pFB5 6.6/5.3 BB
R0603-89 KpnI/Sael pFGl 11 DD
0045H R0595-89 Taql pAFl 2.4/0.7 AA
R0595-89 Bell pFB5 6.6/5.3 BB
R0595-89 KpnI/Sael pFGl 11 DD
0046V R0605-89 Taql pAFl 2.4/1.6/0.7 Aa
R0605-89 Bell pFB5 6.6/5.3 BB
R0605-89 KpnI/SacI pFGl 14/11 Dd
0047E R0584-89 Taql pAFl 2.4/0.7 AA
R0584-89 Bell pFB5 6.6/5.3 BB
R0584-89 KpnI/SacI pFGl 11 DD
0048R R0585-89 Taql pAFl 2.4/0.7 AA
R0585-89 Bell pFB5 6.6/5.3/4.2 Bb
R0585-89 KpnI/SacI pFGl 11 DD
0049B R0608-89 Taql pAFl 2.4/1.6/0.7 Aa
R0608-89 Bell pFB5 6.6/5.3 BB
R0608-89 KpnI/SacI pFGl 14/11 Dd
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0050K R0631-89 Taql pAFl 2.4/0.7 AA
R0631-89 Bell pFB5 6.6/5.3 BB
R0631-89 KpnI/SacI pFGl 11 DD
0051W R0634-89 Taql pAFl 2.4/0.7 AA
R0634-89 Bell pFB5 6.6/5.3 BB
R0634-89 KpnI/SacI pFGl 11 DD
0052H R0643-89 Taql pAFl 2.4/0.7 AA
R0643-89 Bell pFB5 6.6/5.3 BB
R0643-89 KpnI/Sael pFGl 11 DD
0053W R0618-89 Taql pAFl 2.4/0.7 AA
R0618-89 Bell pFB5 6.6/5.3 BB
R0618-89 KpnI/SacI pFGl 11 DD
0055R R0626-89 Taql pAFl 2.4/0.7 AA
R0626-89 Bell pFB5 6.6/5.3 BB
R0626-89 KpnI/SacI pFGl 11 DD
0056B R0655-89 Taql pAFl 2.4/1.6/0.7 Aa
R0655-89 Bell pFB5 6.6/5.3/4.2 Bb
R0655-89 KpnI/SacI pFGl 14/11 Dd
0057M R0632-89 Taql pAFl 2.4/0.7 AA
R0632-89 Bell pFB5 6.6/5.3/4.2 Bb
R0632-89 KpnI/Sael pFGl 11 DD
0058A R0645-89 Taql pAFl 2.4/1.6/0.7 Aa
R0645-89 Bell pFB5 6.6/5.3 BB
R0645-89 KpnI/SacI pFGl 14/11 Dd
0059L R0637-89 Taql pAFl 2.4/0.7 AA
R0637-89 Bell pFB5 6.6/5.3 BB
R0637-89 KpnI/SacI pFGl 11 DD
0060V R0622-89 Taql pAFl 2.4/1.6/0.7 Aa
R0622-89 Bell pFB5 6.6/5.3 BB
R0622-89 KpnI/SacI pFGl 14/11 Dd
0061E R0619-89 Taql pAFl 2.4/1.6/0.7 Aa
R0619-89 Bell pFB5 6.6/5.3 Bb
R0619-89 KpnI/SacI pFGl 14/11 Dd
0062R R0638-89 Taql pAFl 2.4/0.7 AA
R0638-89 Bell pFB5 6.6/5.3 BB
R0638-89 KpnI/SacI pFGl 11 DD
0063B R0623-89 Taql pAFl 2.4/1.6/0.7 Aa
R0623-89 Bell pFB5 6.6/5.3 BB
R0623-89 KpnI/SacI pFGl 14/11 Dd
0064M R0627-89 Taql pAFl 2.4/0.7 AA
R0627-89 Bell pFB5 6.6/4.2 bb
R0627-89 KpnI/Sael pFGl 11 DD
0065A R0635-89 Taql pAFl 2.4/0.7 AA
R0635-89 Bell pFB5 6.6/5.3 BB
R0635-89 KpnI/SacI pFGl 11 DD
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0066L R0633-89 Taql pAFl 2.4/1.6/0.7 Aa
R0633-89 Bell pFB5 6.6/5.3/4.2 Bb
R0633-89 KpnI/SacI pFGl 14/11 Dd
0067X R0620-89 Taql pAFl 2.4/0.7 AA
R0620-89 Bell pFB5 6.6/5.3 BB
R0620-89 KpnI/SacI pFGl 14/11 Dd
0068K R0629-89 Taql pAFl 2.4/0.7 AA
R0629-89 Bell pFB5 6.6/5.3 BB
R0629-89 KpnI/SacI pFGl 11 DD
0069W R0624-89 Taql pAFl 2.4/0.7 AA
R0624-89 Bell pFB5 6.6/5.3 BB
R0624-89 KpnI/SacI pFGl 11 DD
007GB R0653-89 Taql pAFl 2.4/1.6/0.7 Aa
R0653-89 Bell pFB5 6.6/5.3/4.2 Bb
R0653-89 KpnI/SacI pFGl 14/11 Dd
0071M R0630-89 Taql pAFl 2.4/0.7 AA
R0630-89 Bell pFB5 6.6/5.3 BB
R0630-89 KpnI/Sael pFGl 14/11 Dd
0072A R0656-89 Taql pAFl 2.4/0.7 AA
R0656-89 Bell pFB5 6.6/4.2 bb
R0656-89 KpnI/Sael pFGl 11 DD
0073L R0654-89 Taql pAFl 2.4/0.7 AA
R0654-89 Bell pFB5 6.6/5.3 BB
R0654-89 KpnI/SacI pFGl 11 DD
0074X R0663-89 Taql pAFl 2.4/0.7 AA
R0663-89 Bell pFB5 6.6/5.3 BB
R0663-89 KpnI/SacI pFGl 11 DD
0075K R0651-89 Taql pAFl 2.4/0.7 AA
R0651-89 Bell pFB5 6.6/5.3/4.2 Bb
R0651-89 KpnI/SacI pFGl 11 DD
0076W R0646-89 Taql pAFl 2.4/0.7 AA
R0646-89 Bell pFBS 6.6/5.3 BB
R0646-89 KpnI/SacI pFGl 11 DD
0077H R0649-89 Taql pAFl 2.4/1.6/0.7 Aa
R0649-89 Bell pFB5 6.6/5.3 BB
R0649-89 KpnI/Sael pFGl 14/11 Dd
0078V R0659-89 Taql pAFl 2.4/1.6/0.7 Aa
R0659-89 Bell pFB5 6.6/5.3 BB
R0659-89 KpnI/SacI pFGl 14/11 Dd
0079E R0659-89 Taql pAFl 2.4/0.7 AA
R0650-89 Bell pFB5 6.6/5.3 BB
R0650-89 KpnI/SacI pFGl 11 DD
0080L R0657-89 Taql pAFl 2.4/1.6/0.7 Aa
R0657-89 Bell pFB5 6.6/5.3/4.2 Bb
R0657-89 KpnI/Sael pFGl 14/11 Dd
PATIENT NO, LAB NO. ENZYME PROBE RESULTS GENOTYPE
0081X R0666-89 Taql pAFl 2.4/1.6/0.7 Aa
R0666-89 Bell pFB5 6.6/5.3/4.2 Bb
R0666-89 KpnI/Sael pFGl 14/11 Dd
0082K R0636-89 Taql pAFl 2.4/1.6/0.7 Aa
R0636-89 Bell pFB5 6.6/5.3/4.2 Bb
R0636-89 KpnI/Sael pFGl 14/11 Dd
0083W R0642-89 Taql pAFl 2.4/0.7 AA
R0642-89 Bell pFB5 6.6/5.3 BB
R0642-89 KpnI/SacI pFGl 11 DD
0084H R0647-89 Taql pAFl 2.4/0.7 AA
R0647-89 Bell pFB5 6.6/5.3/4.2 Bb
R0647-89 KpnI/SacI pFGl 11 DD
0085V R0625-89 Taql pAFl 2.4/1.6/0.7 Aa
R0625-89 Bell pFB5 6.6/5.3 BB
R0625-89 KpnII/Sae I pFGl 14/11 Dd
0086E R0652-89 Taql pAFl 2.4/0.7 AA
R0652-89 Bell pFB5 6.6/5.3 BB
R0652-89 KpnI/SacI pFGl 11 DD
0087R R0670-89 Taql pAFl 2.4/1.6/0.7 Aa
R0670-89 Bell pFB5 6.6/5.3/4.2 Bb
R0670-89 KpnI/SacI pFGl 11 DD
0088B R0665-89 Taql pAFl 2.4/0.7 AA
R0665-89 Bell pFB5 6.6/5.3 BB
R0665-89 KpnI/Sael pFGl 11 DD
0089M R0668-89 Taql pAFl 2.4/0.7 AA
R0668-89 Bell pFB5 6.6/5.3/4.2 Bb
R0668-89 KpnI/Sael pFGl 11 DD
0090W R0661-89 Taql pAFl 2.4/0.7 AA
R0661-89 Bell pFB5 6.6/5.3/4.2 Bb
R0661-89 KpnI/Sael pFGl 11 DD
0091H R0662-89 Taql pAFl 2.4/1.6/0.7 Aa
R0662-89 Bell pFB5 6.6/5.3 BB
R0662-89 KpnI/Sael pFGl 14/11 Dd
0092V R0669-89 Taql pAFl 2.4/0.7 AA
R0669-89 Bell pFB5 6.6/5.3 BB
R0669-89 KpnI/Sael pFGl 11 DD
0093E R0664-89 Taql pAFl 2.4/0.7 AA
R0664-89 Bell pFB5 6.6/5.3/4.2 Bb
R0664-89 KpnI/Sael pFGl 11 DD
0094R R0660-89 Taq pAFl 1.6/0.7 aa
R0660-89 Bell pFB5 6.6/5.3/4.2 Bb
R0660-89 KpnI/Sael pFGl 14 dd
0095B R0667-89 Taql pAFl 2.4/1.6/0.7 Aa
R0667-89 Bell pFB5 6.6/5.3 BB
R0667-89 KpnI/Sael pFGl 14/11 Dd
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0096M R0640-89 Taql pAFl 2.4/0.7 AA
R0640-89 Bell pFB5 6.6/5.3 BB
RO-86409 KpnI/Sael pFGl 11 Dd
0097A R0641-89 Taql pAFl 2.4/0.7 AA
R0641-89 Bell pFB5 6.6/5.3 BB
R0641-89 KpnI/Sael pFGl 11 DD
0098L R0628-89 Taql pAFl 2.4/1.6/0.7 Aa
R0628-89 Bell pFB5 6.6/5.3 BB
R0628-89 KpnI/SacI pFGl 14/11 Dd
0099X R0648-89 Taql pAFl 2.4/0.7 AA
R0648-89 Bell pFB5 6.6/5.3 BB
R0648-89 KpnI/Sael pFGl 11 DD
OlOOW R0658-89 Taql pAFl 2.4/0.7 AA
R0658-89 Bell pFB5 6.6/5.3 BB
R0658-89 KpnI/Sael pFGl 11 DD
OlOlH R0544-89 Taql pAFl 1.6/0.7 aa
R0544-89 Bell pFB5 6.6/5.3 BB
R0544-89 KpnI/Sael pFGl 14 dd
0102V R0555-89 Taql pAFl 2.4/1.6/0.7 Aa
R0555-89 Bell pFB5 6.6/5.3 BB
R0555-89 KpnI/Sael pFGl 14/11 Dd
0103E R0568-89 Taql pAFl 2.4/1.6/0.7 Aa
R0568-89 Bell pFB5 6.6/5.3 BB
R0568-89 KpnI/SacI pFGl 14/11 Dd
0104 R0558-89 Taql pAFl 2.4/1.6/0.7 Aa
R0558-89 Bell pFB5 6.6/5.3 BB
R0558-89 KpnI/Sael pFGl 14/11 Dd
0105B R0572-89 Taql pAFl 2.4/1.6/0.7 Aa
R0572-89 Bell pFB5 6.6/5.3 BB
R0572-89 KpnI/Sael pFGl 14/11 Dd
0106M R0576-89 Taql pAFl 2.4/0.7 AA
R0576-89 Bell pFB5 6.6/5.3 BB
R0576-89 RpnI/Sael pFGl 11 DD
0108L R0574-89 Taql pAFl 2.4/0.7 AA
R0574-89 Bell pFB5 6.6/5.3 BB
R0574-89 KpnI/Sael pFGl 11 DD
OllOE R0570-89 Taql pAFl 2.4/1.6/0.7 Aa
R0570-89 Bell
R0570-89 KpnI/Sael pFGl 14/11 Dd
OlllR R0563-89 Taql pAFl 2.4/1.6/0.7 Aa
R0563-89 Bell pFB5 6.6/5.3/4.2 Bb
R0563-89 KpnI/Sael pFGl 14/11 Dd
0112B R0566-89 Taql pAFl 2.4/0.7 AA
R0566-89 Bell pFB5 6.6/5.3 BB
R0566-89 KpnI/Sael pFGl 11 DD
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0113M R0550-89 Taql pAFl 2.4/0. 7 AA
R0550-89 Bell pFB5 6.6/5.3 BB
R0550-89 KpnI/Sael pFGl 11 DD
0114A R0565-89 Taql pAFl 2.4/1.6/0.7 Aa
R0565-89 Bell pFB5 6.6/5.3 BB
R0565-89 KpnI/Sael pFGl 14/11 Dd
0115L R0561-89 Taql pAFl 2.4/0.7 AA
R0561-89 Bell pFB5 6.6/5.3 BB
R0561-89 KpnI/Sael pFGl 11 DD
0116X R0573-89 Taql pAFl 2.4/1.6/0.7 Aa
R0573-89 Bell pFB5 6.6/5.3 BB
R0573-89 KpnI/Sael pFGl 11 DD
0117K R0553-89 Taql pAFl 2.4/0.7 AA
R0553-89 Bell pFB5 6.6/5.3/4.2 Bb
R0553-89 KpnI/SacI pFGl 11 DD
0118W R0564-89 Taql pAFl 2.4/0.7 AA
R0564-89 Bell pFB5 6.6/5.3 BB
R0564-89 KpnI/Sael pFGl 11 DD
0119H R0577-89 Taql pAFl 1.6/0.7 aa
R0577-89 Bell pFB5 6.6/5.3 BB
R0577-89 KpnI/SacI pFGl 14 dd
0120M R0559-89 Taql pAFl 2.4/1.6/0.7 Aa
R0599-89 Bell pFB5 6.6/5.3 BB
R0599-89 KpnI/Sael pFGl 14/11 Dd
0121A R0547-89 Taql pAFl 2.4/0.7 AA
R0547-89 Bell pFB5 6.6/5.3 BB
R0547-89 KpnI/Sael pFGl 14/11 Dd
0122L R0548-89 Taql pAFl 2.4/0.7 AA
R0548-89 Bell pFB5 6.6/5.3/4.2 Bb
R0548-89 KpnI/Sael pFGl 11 DD
0123X R0546-89 Taql pAFl 2.4/0.7 AA
R0546-89 Bell pFB5 6.6/5.3/4.2 Bb
R0546-89 KpnI/Sael pFGl 11 DD
0124K R0552-89 Taql pAFl 2.4/1.6/0.7 Aa
R0552-89 Bell pFB5 6.6/5.3 BB
R0552-89 KpnI/Sael pFGl 14/11 Dd
0125W R0545-89 Taql pAFl 2.4/1.6/0.7 Aa
R0545-89 Bell pFB5 6.6/4.2 bb
R0545-89 KpnI/SacI pFGl 14/11 Dd
0126H R0582-89 Taql pAFl 1.6/0.7 aa
R0582-89 Bell pFB5 6.6/5.3 BB
R0582-89 KpnI/SacI pFGl 14 dd
0127V R0549-89 Taql pAFl 2.4/0.7 AA
R0549-89 Bell pFB5 6.6/5.3 BB
R0549-89 KpnI/Sael pFGl 11 DD
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0128E R0554-89 Taql pAFl 2.4/1.6/0.7 Aa
R0554-89 Bell pFB5 6.6/5.3 BB
R0554-89 KpnI/Sael pFGl 14/11 Dd
0130X R0538-89 Taql pAFl 1.6/0.7 aa
R0538-89 Bell pFB5 6.6/5.3 BB
R0538-89 KpnI/Sael pFGl 14 dd
0131K R0537-89 Taql pAFl 2.4/1.6/0.7 Aa
R0537-89 Bell pFB5 6.6/5.3/4.2 Bb
R0537-89 KpnI/SacI pFGl 14/11 Dd
0132W R0541-89 Taql pAFl 2.4/0.7 AA
R0541-89 Bell pFB5 6.6/5.3/4.2 Bb
R0541-89 KpnI/Sael pFGl 11 DD
0134V R0535-89 Taql pAFl 2.4/0.7 AA
R0535-89 Bell pFB5 6.6/5.3 BB
R0535-89 KpnI/SacI pFGl 11 DD
0135E R0542-89 Taql pAFl 2.4/0.7 AA
R0542-89 Bell pFB5 6.6/5.3/4.2 Bb
R0542-89 KpnI/SacI pFGl 11 DD
0136R R0539-89 Taql pAFl 2.4/1.6/0.7 Aa
R0539-89 Bell pFB5 6.6/5.3 BB
R0539-89 KpnI/Sael pFGl 14/11 DD
0138M R0540-89 Taql pAFl 2.4/0.7 AA
R0540-89 Bell pFB5 6.6/5.3 BB
R0540-89 KpnI/Sael pFGl 11 DD
0139A R0671-89 Taql pAFl 2.4/0.7 AA
R0671-89 Bell pFB5 6.6/5.3 BB
R0671-89 KpnI/Sael pFGl 11 DD
0140H R0533-89 Taql pAFl 2.4/0.7 AA
R0533-89 Bell pFB5 6.6/5.3 BB
R0533-89 KpnI/Sael pFGl 11 DD
0143R R0551-89 Taql pAFl 2.4/1.6/0.7 Aa
R0551-89 Bell pFB5 6.6/5.3 BB
R0551-89 KpnI/Sael pFGl 14/11 Dd
0144B R0562-89 Taql pAFl 2.4/0.7 AA
R0562-89 Bell pFB5 6.6/5.3/4.2 Bb
R0562-89 KpnI/Sael pFGl 11 DD
0145M R0578-89 Taql pAFl 2.4/0.7 AA
R0578-89 Bell pFB5 6.6/4.2 bb
R0578-89 KpnI/Sael pFGl 11 DD
0146A R0560-89 Taql pAFl 2.4/0.7 AA
R0560-89 Bell pFB5 6.6/5.3/4.2 Bb
R0560-89 KpnI/SacI pFGl 11 DD
0147L R0580-89 Taql pAFl 2.4/0.7 AA
R0580-89 Bell pFB5 6.6/5.3/4.2 Bb
R0580-89 KpnI/Sael pFGl 11 DD
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0148X R0571-89 Taql pAFl 2.4/0.7 AA
R0571-89 Bell pFB5 6.6/5.3 BB
R0571-89 KpnI/Sael pFGl 11 DD
0149K R0567-89 Taql pAFl 2.4/1.6/0.7 Aa
R0567-89 Bell pFB5 6.6/5.3 BB
R0567-89 KpnI/SacI pFGl 14/11 Dd
0150R R0557-89 Taql pAFl 2.4/0.7 AA
R0557-89 Bell pFB5 6.6/5.3/4.2 Bb
R0557-89 KpnI/Sael pFGl 11 DD
0152M R0714-89 Taql pAFl 2.4/0.7 AA
R0714-89 Bell pFB5 6.6/5.3 BB
R0714-89 KpnI/Sael pFGl 11 DD
0153A R0724-89 Taql pAFl 2.4/0.7 AA
R0724-89 Bell pFB5 6.6/5.3/4.2 Bb
R0724-89 KpnI/Sael pFGl 14/11 Dd
0154L R0794-89 Taql pAFl 2.4/0.7 AA
R0794-89 Bell pFB5 6.6/5.3/4.2 Bb
R0794-89 KpnI/Sael pFGl 11 DD
0155X R0711-89 Taql pAFl 2.4/1.6/0.7 Aa
R0711-89 Bell pFB5 6.6/5.3/4.2 Bb
R0711-89 KpnI/Sael pFGl 14/11 Dd
0156K R0717-89 Taql pAFl 2.4/1.6/0.7 Aa
R0717-89 Bell pFB5 6.6/5.3 BB
R0717-89 KpnI/Sael pFGl 14/11 Dd
0157W R0575-89 Taql pAFl 2.4/0.7 AA
R0575-89 Bell pFB5 6.6/5.3 BB
R0575-89 KpnI/SacI pFGl 11 DD
0158H R0719-89 Taql pAFl 2.4/1.6/0. Aa
R0719-89 Bell pFB5 6.6/5.3 BB
R0719-89 KpnI/Sael pFGl 11 DD
0159V R0698-89 Taql pAFl 2.4/1.6/0.7 Aa
R0698-89 Bell pFB5 6.6/5.3 BB
R0698-89 KpnI/SacI pFGl 14/11 Dd
0160A R0723-89 Taql pAFl 2.4/0.7 AA
R0723-89 Bell pFB5 6.6/5.3 BB
R0723-89 KpnI/SacI pFGl 11 DD
0161L R0715-89 Taql pAFl 2.4/0.7 AA
R0715-89 Bell pFB5 6.6/5.3/4.2 Bb
R0715-89 KpnI/SacI pFGl 11 DD
0162X R0695-89 Taql pAFl 2.4/0.7 AA
R0695-89 Bell pFB5 6.6/5.3 BB
R0695-89 KpnI/Sael pFGl 11 DD
0163K R0718-89 Taql pAFl 2.4/0.7 AA
R0718-89 Bell pFB5 6.6/5.3 BB
R0718-89 KpnI/Sael pFGl 11 DD
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0164W R0713-89 Taql pAFl 2.4/0.7 AA
R0713-89 Bell pFB5 6.6/5.3 BB
R0713-89 KpnI/Sael pFGl 11 DD
0165H R0788-89 Taql pAFl 2.4/0.7 AA
R0788-89 Bell pFB5 6.6/5.3 BB
R0788-89 KpnI/Sael pFGl 11 DD
0167E R0694-89 Taql pAFl 2.4/1.6/0.7 Aa
R0694-89 Bell pFB5 6.6/5.3 BB
R0694-89 KpnI/SacI pFGl 14/11 Dd
0168R R0710-89 Taql pAFl 2.4/07 AA
R0710-89 Bell pFB5 6.6/5.3 BB
R0710-89 KpnI/Sael pFGl 11 DD
0169B R0689-89 Taql pAFl 2.4/0.7 AA
R0689-89 Bell pFB5 6.6/5.3/4.2 Bb
R0689-89 KpnI/Sael pFGl 11 DD
0170K R0708-89 Taql pAFl 2.4/1.6/0.7 Aa
R0708-89 Bell pFB5 6.6/5.3 BB
R0708-89 KpnI/Sael pFGl 14/11 Dd
0171W R0703-89 Taql pAFl 2.4/1.6/0.7 Aa
R0703-89 Bell pFB5 6.6/5.3 BB
R0703-89 KpnI/Sael pFGl 14/11 Dd
0173V R0692-89 Taql pAFl 2.4/1.6/0.7 Aa
R0692-89 Bell pFB5 6.6/5.3 BB
R0692-89 KpnI/Sael pFGl 14/11 Dd
0174E R0683-89 Taql pAFl 2.4/0.7 AA
R0683-89 Bell pFB5 6.6/5.3 BB
R0683-89 KpnI/Sael pFGl 11 DD
0175R R0700-89 Taql pAFl 2.4/0.7 AA
R0700-89 Bell pFB5 6.6/5.3/4.2 Bb
R0700-89 KpnI/Sael pFGl 11 DD
0176B R0709-89 Taql pAFl 2.4/1.6/0.7 Aa
R0709-89 Bell pFB5 6.6/5.3 BB
R0709-89 KpnI/SacI pFGl 14/11 Dd
0177M R0716-89 Taql pAFl 2.4/0.7 AA
R0716-89 Bell pFB5 6.6/5.3 BB
R0716-89 KpnI/SacI pFGl 11 DD
0178A R0720-89 Taql pAFl 1.6/0.7 aa
R0720-89 Bell pFB5 6.6/5.3 BB
R0720-89 KpnI/Sael pFGl 14 dd
0179L R0696-89 Taql pAFl 2.4/0.7 AA
R0696-89 Bell pFB5 6.6/5.3 BB
R0696-89 KpnI/Sael pFGl 11 DD
0180V R0679-89 Taql pAFl 2.4/0.7 AA
R0679-89 Bell pFB5 6.6/5.3 BB
R0679-89 KpnI/Sael pFGl 11 DD
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0181E R0687-89 Taql pAFl 2.4/0.7 AA
R0687-89 Bell pFB5 6.6/5.3/4.2 Bb
R0687-89 KpnI/Sael pFGl 11 DD
0182R R0697-89 Taql pAFl 1.6/0.7 aa
R0697-89 Bell pFB5 6.6/5.3 BB
R0697-89 KpnI/Sael pFGl 14 dd
0183B R0681-89 Taql pAFl 2.4/0.7 AA
R0681-89 Bell pFB5 6.6/5.3 Bb
R0681-89 KpnI/Sael pFGl 11 DD
0184M R0682-89 Taql pAFl 2.4/1.6/0.7 Aa
R0682-89 Bell pFB5 6.6/5.3 BB
R0682-89 KpnI/Sael pFGl 14/11 Dd
0185A R0706-89 Taql pAFl 2.4/0.7 AA
R0706-89 Bell pFB5 6.6/5.3 BB
R0706-89 KpnI/Sae I pFGl 11 DD
0186L R0691-89 Taql pAFl 2.4/0.7 AA
R0691-89 Bell pFB5 6.6/5.3 BB
R0691-89 KpnI/Sael pFGl 11 DD
0187X R0680-89 Taql pAFl 2.4/0.7 AA
R0680-89 Bell pFB5 6.6/5.3 BB
R0680-89 KpnI/Sael pFGl 11 DD
0188K R0688-89 Taql pAFl 2.4/1.6/0.7 Aa
R0688-89 Bell pFB5 6.6/5.3/4.2 Bb
R0688-89 KpnI/Sael pFGl 14/11 Dd
0189W R0678-89 Taql pAFl 2.4/0.7 AA
R0678-89 Bell pFB5 6.6/5.3 BB
R0678-89 KpnI/Sael pFGl 11 DD
019GB R0690-89 Taql pAFl 2.4/0.7 AA
R0690-89 Bell pFB5 6.6/5.3/4.2 Bb
R0690-89 KpnI/Sael pFGl 11 DD
0191M R0693-89 Taql pAFl 2.4/0.7 AA
R0693-89 Bell pFB5
R0693-89 KpnI/Sael pFGl 11 DD
0192E R0722-89 Taql pAFl 2.4/0.7 AA
R0722-89 Bell pFB5 6.6/5.3/4.2 Bb
R0722-89 KpnI/SacI pFGl 11 DD
0193L R0702-89 Taql pAFl 2.4/1.6/0.7 Aa
R0702-89 Bell pFB5 6.6/5.3 BB
R0702-89 KpnI/Sael pFGl 11 DD
0194X R0699-89 Taql pAFl 2.4/1.6/0.7 Aa
R0699-89 Bell pFB5 6.6/5.3 BB
R0699-89 KpnI/SacI pFGl 11 DD
0195K R0686-89 Taql pAFl 2.4/1.6/0.7 Aa
R0686-89 Bell pFB5 6.6/5.3 BB
R0686-89 KpnI/Sael pFGl 11 DD
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0196W R0707-89 Taql pAFl 2.4/0.7 AA
R0707-89 Bell pFB5 6.6/5.3/4.2 Bb
R0707-89 KpnI/Sael pFGl 11 DD
0197H R0704-89 Taql pAFl 2.4/1.6/0.7 Aa
R0704-89 Bell pFB5 6.6/5.3 BB
R0704-89 KpnI/SacI pFGl 14/11 Dd
0198V R0684-89 Taql pAFl 2.4/1.6/0.7 Aa
R0684-89 Bell pFB5 6.6/5.3/4.2 Bb
R0684-89 KpnI/Sael pFGl 14/11 Dd
0199E R0685-89 Taql pAFl 2.4/1.6/0.7 Aa
R0685-89 Bell pFB5 6.6/5.3 BB
R0685-89 KpnI/SacI pFGl 14/11 Dd
0201M R0676-89 Taql pAFl 2.4/0.7 AA
R0676-89 Bell pFB5 6.6/5.3 BB
R0676-89 KpnI/Sael pFGl 11 DD
0202E R0672-89 Taql pAFl 2.4/1.6/0.7 Aa
R0672-89 Bell pFB5 6.6/5.3 BB
R0672-89 KpnI/SacI pFGl 11 DD
0203L R0677-89 Taql pAFl 2.4/1.6/0.7 Aa
R0677-89 Bell pFB5 6.6/5.3/4.2 Bb
R0677-89 KpnI/Sael pFGl 14/11 Dd
0204X R0673-89 Taql pAFl 2.4/0.7 AA
R0673-89 Bell pFB5 6.6/5.3 BB
R0673-89 KpnI/SacI pFGl 11 DD
0205K R0674-89 Taql pAFl 2.4/1.6/0.7 Aa
R0674-89 Bell pFB5 6.6/5.3 BB
R0674-89 KpnI/SacI pFGl 14/11 Dd
0206W R0801-89 Taql pAFl 2.4/1.6/0.7 Aa
R0801-89 Bell pFB5 6.6/5.3 BB
R0801-89 KpnI/SacI pFGl 14/11 Dd
0207H R0816-89 Taql pAFl 2.4/1.6/0.7 Aa
R0816-89 Bell pFB5 6.6/5.3 BB
R0816-89 KpnI/Sael pFGl 11 DD
0210L R0799-89 Taql pAFl 2.4/0.7 AA
R0799-89 Bell pFB5 6.6/5.3 BB
R0799-89 KpnI/SacI pFGl 11 DD
0211X R0797-89 Taql pAFl 2.4/0.7 AA
R0797-89 Bell pFB5 6.6/5.3 BB
R0797-89 KpnI/SacI pFGl 11 DD
0212K R0803-89 Taql pAFl 2.4/0.7 AA
R0803-89 Bell pFB5 6.6/5.3 BB
R0803-89 KpnI/SacI pFGl 11 DD
0213W R0789-89 Taql pAFl 2.4/1.6/0.7 Aa
R0789-89 Bell pFB5 6.6/5.3 BB
R0789-89 KpnI/SacI pFGl 11 DD
PATIENT NO, LAB NO. ENZYME PROBE RESULTS GENOTYPE
0214H R0812-89 TaqI pAFl 1.6/0.7 aa
R0812-89 Bell pFB5 6.6/5.3 BB
R0812-89 KpnI/SacI pFGl 14 dd
0215V R0819-89 TaqI . pAFl 2.4/1.6/0.7 Aa
R0819-89 Bell pFB5 6.6/5.3 BB
R0819-89 KpnI/Sael pFGl 14/11 Dd
0217R R0820-89 TaqI pAFl 1.6/0.7 aa
R0820-89 Bell pFB5 6.6/5.3 BB
R0820-89 KpnI/Sael pFGl 14/11 Dd
0218B R0811-89 TaqI pAFl 2.4/0.7 AA
R0811-89 Bell pFB5 6.6/5.3 BB
R0811-89 KpnI/Sael pFGl 11 DD
0219M R0798-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0798-89 Bell pFB5 6.6/5.3 BB
R0798-89 KpnI/Sael pFGl 14/11 Dd
0221H R0786-89 TaqI pAFl 2.4/0.7 AA
R0786-89 Bell pFB5 6.6/5.3 BB
R0786-89 KpnI/Sael pFGl 11 DD
0223E R0806-89 TaqI pAFl 2.4/1.6/0.7 Aa
R08Q6-89 Bell pFB5 6.6/5.3 BB
R0806-89 KpnI/Sael pFGl 14/11 Dd
0225B R0810-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0810-89 Bell pFB5 6.6/5.3 BB
R0810-89 KpnI/Sael pFGl 14/11 Dd
0227A R0822-89 TaqI pAFl 2.4/0.7 AA
R0822-89 Bell pFB5 6.6/5.3/4.2 Bb
R0822-89 KpnI/Sael pFGl 11 DD
0228L R0817-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0817-89 Bell pFB5 6.6/5.3 BB
R0817-89 KpnI/Sael pFGl 14/11 Dd
0229X R0813-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0813-89 Bell pFB5 6.6/5.3 BB
R0813-89 KpnI/Sael pFGl 14/11 Dd
0230E R0800-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0800-89 Bell pFB5 6.6/5.3/4.2 Bb
R0800-89 KpnI/Sael pFGl 14/11 Dd
0231R R0823-89 TaqI pAFl 2.4/0.7 AA
R0823-89 Bell pFB5 6.6/5.3 BB
R0823-89 KpnI/Sael pFGl 11 DD
0232B R0825-89 TaqI pAFl 2.4/0.7 AA
R0825-89 Bell pFB5 6.6/5.3/4.2 BB
R0825-89 KpnI/Sael pFGl 11 DD
0233M R0826-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0826-89 Bell pFB5 6.6/5.3/4.2 Bb
R0826-89 KpnI/Sael pFGl 14/11 Dd
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0234A R0808-89 TaqI pAFl 2.4/0.7 AA
R0808-89 Bell pFB5 6.6/5.3 BB
R0808-89 KpnI/Sael pFGl 11 DD
0235L R0821-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0821-89 Bell pFB5 6.6/5.3/4.2 Bb
R0821-89 KpnI/Sael pFGl 14/11 Dd
0236X R0807-89 TaqI pAFl 2.4/0.7 AA
R0807-89 Bell pFB5 6.6/5.3 BB
R0807-89 KpnI/Sael pFGl 11 DD
0237K R0829-89 TaqI pAFl 2.4/1.6/0.7 aa
R0829-89 Bell pFB5 6.6/5.3 BB
R0829-89 KpnI/Sael pFGl 14/11 Dd
0238W R0828-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0828-89 Bell pFB5 6.6/5.3 BB
R0828-89 KpnI/Sael pFGl 14/11 Dd
0239H R0827-89 TaqI pAFl 2.4/1.6/0.7 AA
R0827-89 Bell pFB5 6.6/5.3 BB
R0827-89 KpnI/Sael pFGl 14/11 Dd
0240M R0802-89 TaqI pAFl 2.4/0.7 AA
R0802-89 Bell pFB5 6.6/5.3 BB
R0802-89 KpnI/Sael pFGl 11 DD
0241A R0818-89 TaqI pAFl 2.4/0.7 AA
R0818-89 Bell pFB5 6.6/5.3 BB
R0818-89 Kpnl/Sael pFGl 11 DD
0242L R0785-89 TaqI pAFl 1.6/0.7 aa
R0785-89 Bell pFB5 6.6/5.3 BB
R0785-89 KpnI/Sael pFGl 14 dd
0243X R0815-89 TaqI pAFl 2.4/0.7 AA
R0815-89 Bell pFB5 6.6/5.3 BB
R0815-89 KpnI/Sael pFGl 11 DD
0245W R0809-89 TaqI pAFl 2.4/0.7 AA
R0809-89 Bell pFB5 6.6/5.3 BB
R0809-89 KpnI/Sael pFGl 11 DD
0247V R0805-89 TaqI pAFl 2.4/0.7 AA
R0805-89 Bell pFB5 6.6/5.3 BB
R0805-89 KpnI/Sael pFGl 14/11 Dd
0249R R0824-89 TaqI pAFl 2.4/0.7 AA
R0824-89 Bell pFB5 6.6/5.3 BB
R0824-89 KpnI/Sael pFGl 14/11 Dd
0250X R0784-89 TaqI pAFl 2.4/0.7 AA
R0784-89 Bell pFB5 6.6/5.3 BB
R0784-89 KpnI/Sael pFGl 11 DD
0252W R0790-89 TaqI pAFl 2.4/1.6/0.7 Aa
R0790-89 Bell pFB5 6.6/5.3 BB
R0790-89 KpnI/Sael pFGl 14/11 Dd
PATIENT NO. LAB NO. ENZYME PROBE RESULTS GENOTYPE
0251K R0791-89 TaqI pAFl 1.6/0.7 aa
R0791-89 Bell pFB5 6.6/5.3 BB
R0791-89 KpnI/Sael pFGl 14 dd
0253H R0134-89 Taql pAFl 1.6/0.7 aa
R0134-89 Bell pFB5 6.6/5.3 BB
R0134-89 KpnI/Sael pFGl 14 dd
0254V R0139-89 Taql pAFl 2.4/0.7 AA
R0139-89 Bell pFB5 6.6/5.3 BB
R0139-89 KpnI/Sael pFGl 11 DD
0255E R0130-89 Taql pAFl 2.4/1.6/0.7 Aa
R0130-89 Bell pFB5 6.6/5.3 BB
R0130-89 KpnI/Sael pFGl 14/11 Dd
0257B R0138-89 Taql pAFl 2.4/1.6/0.7 Aa
R0138-89 Bell pFB5 6.6/4.2 bb
R0138-89 KpnI/Sael pFGl 14/11 Dd
0259A R0141-89 Taql pAFl 2.4/0.7 AA
R0141-89 Bell pFB5 6.6/5.3 BB
R0141-89 KpnI/Sael pFGl 11 DD
0260H R0140-89 Taql pAFl 2.4/0.7 AA
R0140-89 Bell pFB5 6.6/5.3 BB
R0140-89 KpnI/Sael pFGl 14/11 Dd
0261V R0136-89 Taql pAFl 2.4/0.7 AA
R0136-89 Bell pFB5 6.6/5.3 BB
R0136-89 KpnI/Sael pFGl 11 DD
0262E R0131-89 Taql pAFl 2.4/0.7 AA
R0131-89 Bell pFB5 6.6/5.3 BB
R0131-89 KpnI/Sael pFGl 11 DD
0263R R0133-89 Taql pAFl 2.4/1.6/0.7 Aa
R0133-89 Bell pFB5 6.6/5.3 BB
R0133-89 KpnI/Sael pFGl 14/11 Dd
Fibrinogen genotype
APPENDIX 3
results in the peripheral
case-control study for the Haelll polymorphism usina
chain reaction (PCR) 
PATIENT NO. LAB NO. ENZYME RESULTS
0003X R0329-89 Haelll H1H2
0004K R0326-89 Haelll HlHl
0005W R0523-89 Haelll HlHl
0006H R0322-89 Haelll
0007V R0328-89 Haelll H1H2
0008E R0327-89 Haelll
0009R R0325-89 Haelll H1H2
OOlOX R0324-89 Haelll H1H2
OOllK R0612-89 Haelll HlHl
0012W R0614-89 Haelll H1H2
0013H R0617-89 Haelll HlHl
0014V R0616-89 Haelll H1H2
0015E R0599-89 Haelll HlHl
0016R R0615-89 Haelll HlHl
0017B R0597-89 Haelll H1H2
0020H R0587-89 Haelll HlHl
0021V R0613-89 Haelll H1H2
0022E R0594-89 Haelll
0023R R0600-89 Haelll H1H2
0024B R0598-89 Haelll
0025M R0589-89 Haelll HlHl
0026A R0593-89 Haelll H1H2
0027L R0596-89 Haelll HlHl
0028X R0604-89 Haelll HlHl
0029K R0610-89 Haelll HlHl
0030V R0793-89 Haelll H2H2
0032M R0583-89 Haelll HlHl
0033A R0601-89 Haelll
0034L R0621-89 Haelll
0035X R0581-89 Haelll H1H2
0036K R0590-89 Haelll
0037W R0588-89 Haelll HlHl
0038H R0609-89 Haelll
0039V R0586-89 Haelll HlHl
0040A R0607-89 Haelll
0041K R0591-89 Haelll H1H2
0042X R0592-89 Haelll H1H2
0043K R0606-89 Haelll
0044W R0603-89 Haelll HlHl
0045H R0595-89 Haelll
0046V R0605-89 Haelll HlHl
0047E R0584-89 Haelll
0048R R0585-89 Haelll H1H2
0049B R0608-89 Haelll HlHl
0050K R0631-89 Haelll
0051W R0634-89 Haelll HlHl
0052H R0643-89 Haelll HlHl
0053W R0618-89 Haelll HlHl
0055R R0626-89 Haelll
0056B R0655-89 Haelll H1H2
0057M R0632-89 Haelll H1H2
0058A R0645-89 Haelll HlHl
0059L R0637-89 Haelll HlHl
0060V R0622-89 Haelll HlHl
vascular disease 
I the polymerase
PATIENT NO, LAB NO. ENZYME RESULTS
0061E R0619-89 Haelll HlHl
0062R R0638-89 Haelll H2H2
0063B R0623-89 Haelll HlHl
0064M R0627-89 Haelll H2H2
0065A R0635-89 Haelll
0066L R0633-89 Haelll H2H2
0067X R0620-89 Haelll HlHl
0068R R0629-89 Haelll HlHl
0069W R0624-89 Haelll HlHl
0070B R0653-89 Haelll HlHl
0071M R0630-89 Haelll
0072A R0656-89 Haelll
0073L R0654-89 Haelll
0074X R0663-89 Haelll
0075K R0651-89 Haelll H1H2
0076W R0646-89 Haelll
0077H R0649-89 Haelll HlHl
0078V R0659-89 Haelll HlHl
0079E R0659-89 Haelll HlHl
0080L R0657-89 Haelll H1H2
0081X R0666-89 Haelll H1H2
0082K R0636-89 Haelll
0083W R0642-89 Haelll HlHl
0084H R0647-89 Haelll
0085V R0625-89 Haelll
0086E R0652-89 Haelll HlHl
0087R R0670-89 Haelll H1H2
0088B R0665-89 Haelll
0089M R0668-89 Haelll
0090W R0661-89 Haelll H2H2
0091H R0662-89 Haelll HlHl
0092V R0669-89 Haelll
0093E R0664-89 Haelll H1H2
0094R R0660-89 Haelll H1H2
0095B R0667-89 Haelll HlHl
0096N R0640-89 Haelll
0097A R0641-89 Haelll HlHl
0098L R0628-89 Haelll
0099X R0648-89 Haelll HlHl
OlOOW R0658-89 Haelll
OlOlH R0544-89 Haelll HlHl
0102V R0555-89 Haelll HlHl
0103E R0568-89 Haelll HlHl
0104R R0558-89 Haelll HlHl
0105B R0572-89 HaelII HlHl
0106M R0576-89 Haelll H1H2
0108L R0574-89 HaelII HlHl
OllOE R0570-89 Haelll
OlllR R0563-89 Haelll H1H2
0112B R0566-89 Haelll
0113M R0550-89 Haelll HlHl
0114A R0565-89 Haelll HlHl
0115L R0561-89 Haelll
0116X R0573-89 Haelll HlHl
0117K R0553-89 Haelll H1H2
0118W R0564-89 Haelll H1H2
0119H R0577-89 Haelll HlHl
0120M R0559-89 Haelll HlHl
0121A R0547-89 Haelll
0122L R0548-89 Haelll H1H2
PATIENT NO. LAB NO. ENZYME RESULTS
0123X R0546-89 Haelll H1H2
0124K R0552-89 Haelll HlHl
0125W R0545-89 Haelll H1H2
0126H R0582-89 Haelll HlHl
0127V R0549-89 Haelll
0128E R0554-89 Haelll HlHl
0130X R0538-89 Haelll HlHl
0131K R0537-89 Haelll
0132W R0541-89 Haelll
0134V R0535-89 Haelll HlHl
0135E R0542-89 HaelII H1H2
0136R R0539-89 Haelll
0138M R0540-89 Haelll
0139A R0671-89 Haelll HlHl
0140H R0533-89 Haelll HlHl
0143R R0551-89 Haelll HlHl
0144B R0562-89 Haelll HlHl
0145M R0578-89 Haelll H1H2
0146A R0560-89 Haelll
0147L R0580-89 Haelll
0148X R0571-89 Haelll
0149K R0567-89 Haelll HlHl
0150R R0557-89 Haelll H1H2
0152N R0714-89 Haelll
0153A R0724-89 Haelll
0154L R0794-89 Haelll H1H2
0155X R0711-89 Haelll H1H2
0156K R0717-89 Haelll
0157W R0575-89 Haelll HlHl
0158H R0719-89 Haelll
0159V R0698-89 Haelll HlHl
0160A R0723-89 Haelll HlHl
0161L R0715-89 Haelll
0162X R0695-89 Haelll
0163K R0718-89 Haelll HlHl
0164W R0713-89 Haelll HlHl
0165H R0788-89 Haelll HlHl
0167E R0694-89 Haelll HlHl
0168R R0710-89 Haelll H1H2
0169B R0689-89 Haelll H1H2
0170K R0708-89 Haelll HlHl
0171W R0703-89 Haelll HlHl
0173V R0692-89 Haelll
0174E R0683-89 Haelll HlHl
0175R R0700-89 Haelll HlHl
0176B R0709-89 Haelll HlHl
0177M R0716-89 Haelll HlHl
0178A R0720-89 Haelll HlHl
0179L R0696-89 Haelll
0180V R0679-89 Haelll HlHl
0181E R0687-89 Haelll H1H2
0182R R0697-89 Haelll
0183B R0681-89 Haelll HlHl
0184M R0682-89 Haelll HlHl
0185A R0706-89 Haelll HlHl
0186L R0691-89 Haelll
0187X R0680-89 Haelll HlHl
0188K R0688-89 Haelll H1H2
0189W R0678-89 Haelll HlHl
0190B R0690-89 Haelll H2H2
PATIENT NO. LAB NO. ENZYME RESU
0191M R0693-89 Haelll HlHl
0192E R0722-89 Haelll H2H2
0193L R0702-89 Haelll
0194X R0699-89 Haelll
0195K R0686-89 Haelll HlHl
0196W R0707-89 Haelll
0197H R0704-89 Haelll HlHl
0198V R0684-89 Haelll H1H2
0199E R0685-89 Haelll HlHl
0201M R0676-89 Haelll HlHl
0202E R0672-89 Haelll HlHl
0203L R0677-89 Haelll H1H2
0204X R0673-89 Haelll HlHl
0205R R0674-89 Haelll HlHl
0206W R0801-89 Haelll
0207H R0816-89 Haelll HlHl
0210L R0799-89 Haelll
0211X R0797-89 Haelll
0212K R0803-89 Haelll HlHl
0213W R0789-89 Haelll HlHl
0214H R0812-89 Haelll HlHl
0215V R0819-89 Haelll HlHl
0217R R0820-89 Haelll HlHl
0218B R0811-89 Haelll HlHl
0219M R0798-89 Haelll HlHl
0221H R0786-89 Haelll HlHl
0223E R0806-89 Haelll HlHl
0225B R0810-89 Haelll HlHl
0227A R0822-89 Haelll H1H2
0228L R0817-89 Haelll HlHl
0229X R0813-89 Haelll
0230E R0800-89 Haelll H1H2
0231R R0823-89 Haelll HlHl
0232B R0825-89 Haelll H1H2
0233M R0826-89 Haelll H1H2
0234A R0808-89 Haelll
0235L R0821-89 Haelll H1H2
0236X R0807-89 Haelll HlHl
0237K R0829-89 Haelll HlHl
0238W R0828-89 Haelll HlHl
0239H R0827-89 Haelll HlHl
0240M R0802-89 Haelll HlHl
0241A R0818-89 Haelll HlHl
0242L R0785-89 Haelll HlHl
0243X R0815-89 Haelll H1H2
0245W R0809-89 Haelll HlHl
0247V R0805-89 Haelll HlHl
0249R R0824-89 Haelll HlHl
0250X R0784-89 Haelll HlHl
0252W R0790-89 Haelll HlHl
0253H R0134-89 Haelll HlHl
0254V R0139-89 Haelll
0255E R0130-89 Haelll
0257B R0138-89 Haelll
0259A R0141-89 HaelII
0260H R0140-89 Haelll HlHl
0261V R0136-89 Haelll HlHl
0262E R0131-89 Haelll HlHl
0263R R0133-89 Haelll HlHl
APPENDIX 4
Fibrinogen genotype results in the Ladywell subjects with a polarised 
predisposition to high and low blood pressure.
PATIENT NUMBER RESULT GENOTYPE
10082 6.6/5.3 BB
10083 6.6/5.3 BB
10121 6.6/5.3/4.2 Bb
10173 6.6/5.3 BB
10252 6.6/5.3 BB
10371 6.6/5.3 BB
10502 6.6/5.3 BB
10531 6.6/5.3 BB
10592
10621 6.6/5.3/4.2 Bb
10622 6.6/5.3/4.2 Bb
10892 6.6/5.3 BB
10921
10943 6.6/5.3 BB
10952
10953 6.6/5.3 BB
11001 6.6/5.3 BB
11002
11062 6.6/5.3/4.2 Bb
11232
11252 6.6/5.3/4.2 Bb
11291 6.6/5.3/4.2 Bb
11352 6.6/5.3 BB
11362 6.6/5.3 BB
11453 6.6/5.3 BB
11543 6.6/5.3 BB
11611 6.6/5.3 BB
11722
11842 6.6/5.3 BB
11914
11924 6.6/5.3 BB
11951 6.6/5.3/4.2 Bb
11952 6.6/5.3/4.2 Bb
12062 6.6/5.3 BB
12063 6.6/5.3 BB
12111 6.6/5.5/4.2 Bb
12112 6.6/5.3 BB
12132 6.6/5.3/4.2 Bb
12203 6.6/5.3/4.2 Bb
12251 6.6/5.3 BB
12252 6.6/5.3 BB
12281 6.6/5.3/4.2 Bb
12513 6.6/5.3 BB
12594 6.6/5.3 Bb
12792 6.6/5.3/4.2 Bb
12902
12922 6.6/5.3 BB
12942
12982 6.6/5.3 BB
12983 6.6/5.3 BB
13003 6.6/5.3/4.2 Bb
13101 6.6/5.3 BB
13102 6.6/5.3 BB
13122 6.6/5.3 BB
13222 6.6/5.3/4.2 Bb
PATIENT NUMBER RESULT GENOTYPE
13241 6.6/5.3 BB
13421 6.6/5.3 BB
13423 6.6/5.3 BB
13642 
13654
13684 6.6/5.3 BB
13802 6.6/5.3 BB
13862 6.6/5.3 BB
13911 6.6/5.3 BB
14013 6.6/5.3 BB
14024 6.6/5.3 BB
14051 6.6/5.3/4.2 Bb
14241 6.6/5.3 BB
14242
14323 6.6/5.3 BB
14332 6.6/5.3 BB
14542
14582 6.6/4.2 bb
14622 6.6/5.3/4.2 Bb
14642 6.6/5.3/4.2 Bb
14672 6.6/5.3 BB
14763 6.6/5.3 BB
14792 6.6/5.3/4.2 Bb
14882 6.6/5.3/4.2 Bb
14911
14974 6.6/5.3/4.2 Bb
12982 6.6/4.2 bb
15082 6.6/5.3/4.2 Bb
15282 6.6/5.3 BB
15502
15601 6.6/5.3 BB
15691 6.6/5.3/4.2 Bb
15723 6.6/5.3 BB
15771 6.6/5.3/4.2 Bb
15833
15932 6.6/5.3 BB
16111 6.6/5.3/4.2 Bb
16182 6.6/5.3 BB
16301
16332 6.6/5.3/4.2 Bb
16382 6.6/5.3 BB
16531 6.6/5.3/4.2 Bb
16621
16701 6.6/5.3 BB
16702 6.6/5.3/4.2 Bb
16771 6.6/5.3 BB
16841 6.6/5.3/4.2 Bb
17052 6.6/5.3/4.2 Bb
17161 6.6/5.3/4.2 Bb
17321 6.6/5.3 BB
17371 6.6/4.2 bb
17551 6.6/5.3 BB
17671 6.6/5.3 BB
17672 6.6/5.3 BB
17892 6.6/5.3 BB
20072 6.6/5.3/4.2 Bb
20091
20131 6.6/5.3 BB
20142 6.6/5.3 BB
20152 6.6/5.3 BB
PATIENT NUMBER RESULT GENOTYPE
20252 6.6/5.3/4.2 Bb
20253 6.6/5.3 BB
20351 6.6/5.3 BB
20422 6.6/5.3 BB
20423 6.6/5.3 BB
20472
20553 6.6/5.3 BB
20561 6.6/5.3 BB
20682 6.6/5.3 BB
20741 6.6/5.3 BB
21052 6.6/5.3 BB
21192 6.6/5.3 BB
21222 6.6/5.3 BB
21272
21332 6.6/5.3/4.2 Bb
21451
21522 6.6/5.3 BB
21702 6.6/5.3 BB
21714 6.6/5.3 BB
21722 6.6/5.3 BB
21843 6.6/5.3/4.2 Bb
22023
22024 6.6/5.3 BB
22112
22381 6.6/5.3 BB
22752 6.6/5.3 BB
22762 6.6/5.3 BB
22942 6.6/5.3/4.2 Bb
23061 6.6/5.3 BB
23082 6.6/5.3 BB
23256 6.6/5.3 BB
23293 6.6/5.3 BB
23393 6.6/4.2 bb
23403 6.6/5.3 BB
23452 6.6/5.3 BB
23523 6.6/5.3 BB
23583 6.6/5.3 BB
23662 6.6/5.3 BB
23691 6,6/5.3/4.2 Bb
23793 6.6/5.3/4.2 Bb
23892
23952 6.6/5.3 BB
24011 6.6/5.3/4.2 Bb
24113 6.6/5.3 Bb
24261
24262 6.6/5.3 BB
24301 6.6/5.3 BB
24302 6.6/5.3 BB
24363 6.6/5.3 BB
24372 6.6/5.3 BB
24492 6.6/5.3 BB
24516
24521 6.6/5.3 BB
24531
24682
24721 6.6/5.3 BB
24751 6.6/5.3/4.2 Bb
24752 6.6/5.3 BB
24762 6.6/5.3/4.2 Bb
24821 6.6/5.3 BB
PATIENT NUMBER RESULT GENOTYPE
24931 6.6/5.3/4.2 Bb
25142 6.6/5.3 BB
25143 6.6/5.3/4.2 Bb
25202
25303 6.6/5.3 BB
25311 6.6/5.3/4.2 Bb
25331 6.6/5.3 BB
25361 6.6/5.3 BB
25371 6.6/5.3 BB
25544 6.6/4.2 bb
25553 6.6/5.3 BB
25684 6.6/5.3 BB
25685 6.6/5.3 BB
25751 6.6/5.3/4.2 Bb
25814 6.6/5.3 BB
25852 6.6/5.3/4.2 Bb
25863 6.6/5.3 BB
25864 6.6/5.3 BB
25942 6.6/5.3 BB
25962 6.6/5.3 BB
26093 6.6/5.3 BB
26132
26191 6.6/5.3 BB
26241 6.6/5.3 BB
26242
26262 6.6/5.3 BB
26331
26372 6.6/5.3 BB
26521
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